[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 723
1. Gogo-Abite M, Seleye-Fubara D, Jamabo RS: Fibroadenoma coexisting with infiltrating ductal carcinoma--a case report. Niger J Med; 2005 Apr-Jun;14(2):221-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Fibroadenomas are benign breast tumours that are commonly diagnosed in young women in their 20's and early 30's.
  • Occurrence of malignancy in the breasts of these women is very rare.
  • METHOD AND RESULT: We report a case of an infiltrating ductal carcinoma within an otherwise benign fibroadenoma in a 23-year-old woman.
  • She presented with a lump, approximately 7cm in diameter, in her right breast.
  • CONCLUSION: Fibroadenomas are commonly diagnosed in patients in their 20's when the risk of developing breast cancer is extremely rare.
  • Despite this rarity all excised breast lumps should be subjected to histopathological evaluation in order to avoid a diagnostic pitfall.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083250.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


2. Rinaldi P, Giuliani M, Belli P, Costantini M, Romani M, Distefano D, Bufi E, Mulè A, Magno S, Masetti R, Bonomo L: DWI in breast MRI: role of ADC value to determine diagnosis between recurrent tumor and surgical scar in operated patients. Eur J Radiol; 2010 Aug;75(2):e114-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DWI in breast MRI: role of ADC value to determine diagnosis between recurrent tumor and surgical scar in operated patients.
  • INTRODUCTION: Purpose of our study is to evaluate the role of the apparent diffusion coefficient (ADC) in the diagnosis of recurrent tumor on the scar in patients operated for breast cancer.
  • Assess, therefore, the weight of diagnostic diffusion echo-planar sequence, in association with the morphological and dynamic sequences in the diagnosis of tumor recurrence versus surgical scar.
  • MATERIALS AND METHODS: From September 2007 to March 2009, 72 patients operated for breast cancer with suspected recurrence on the scar were consecutively subjected to magnetic resonance imaging (MRI), including use of a diffusion sequence.
  • RESULTS: 26 cases were positive/doubtful at MRI and then subjected to histological typing: of these recurrences were 20 and benign were 6.
  • CONCLUSIONS: ADC value can be a specific parameter in differential diagnosis between recurrence and scar.
  • The diffusion sequence, in association with the morphological and dynamic sequences, can be considered a promising tool for the surgical indication in suspected recurrence of breast cancer.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Cicatrix / diagnosis. Diffusion Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20172677.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


3. Du J, Shi XY, Zheng J, Zhou M, Cui X: [Antigen retrieval immunohistochemistry under the influence of pH value and time]. Beijing Da Xue Xue Bao; 2005 Apr 18;37(2):195-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The following tissues were fixed in 10% formalin: the tissues of prostate carcinoma, benign prostate hyperplasia, proliferative breast disease and cunnus epithelial tissue infected by human papilloma virus.
  • The first antibodies were P504S for prostate carcinoma, P63 for benign prostate hyperplasia, CD10 for proliferative breast disease, and Ki-67 for cunnus epithelial tissue infected by human papilloma virus.
  • [MeSH-major] Antigen-Antibody Complex / analysis. Antigens / analysis. Neoplasms / immunology
  • [MeSH-minor] Antigens, Neoplasm / analysis. Antigens, Neoplasm / immunology. Buffers. Hydrogen-Ion Concentration. Immunohistochemistry / methods. Staining and Labeling / methods. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841154.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigen-Antibody Complex; 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Buffers
  •  go-up   go-down


Advertisement
4. Wang F, Wang Z, Wu J, Qu W, Yao W, Zhao J, Liu Z: The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR. Nucl Med Biol; 2008 Aug;35(6):665-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR.
  • PURPOSE: To evaluate the value of (99m)Tc-octreotide acetate (hereafter, (99m)Tc-octreotide) somatostatin receptor (SSTR) scintigraphy in the detection of primary breast cancer and to correlate with expression of SSTRs.
  • MATERIALS AND METHODS: Fifty-four female and 1 male patients (range, 17-77 years; mean age, 48 years) with palpable breast lesion were included in this study. (99m)Tc-octreotide and (99m)Tc-MIBI scintigraphy were undertaken in all patients, and the region of interest was drawn around each lesion.
  • Tumor uptake was measured and expressed as the ratio of tumor to normal tissue activity (T/NT).
  • Final clinical diagnosis was confirmed by histopathological analysis.
  • Expression of SSTR1-5 mRNA was measured with RT-PCR in 15 patients with malignant neoplasm, and protein level of SSTR-2 and SSTR-5 was measured using immunohistochemical staining in 15 patients with malignant neoplasm and 18 patients with benign lesion.
  • RESULTS: Thirty-five patients were confirmed to have infiltrative ductal breast carcinoma, 1 patient with cellular cancer, 1 patient with adenocarcinoma and 18 patients had benign lesions.
  • CONCLUSION: (99m)Tc-octreotide acetate scintigraphy was sensitive for the detection of primary lesion of breast cancer; however, nonspecific breast tissue uptake hampered the specificity and clinical value in the detection of lymph node metastasis.
  • Five subtypes of SSTR mRNA and protein SSTR2 and SSTR5 were expressed variably in breast cancer due to tumor heterogeneity. (99m)Tc-octreotide imaging may hold promise in the evaluation of the level of SSTR2 in vivo.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / radionuclide imaging. Octreotide / analogs & derivatives. Organotechnetium Compounds / pharmacokinetics. Receptors, Somatostatin / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18678351.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


5. Zhou S, Xu Z, Ling XF, Li QB, Xu YZ, Zhang L, Zhao HM, Wang LX, Hou KY, Zhou XS, Wu JG: [FTIR spectroscopic characterization of freshly removed breast cancer tissues]. Zhonghua Zhong Liu Za Zhi; 2006 Jul;28(7):512-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [FTIR spectroscopic characterization of freshly removed breast cancer tissues].
  • OBJECTIVE: To identify the FTIR spectroscopic characterization of breast cancer and explore the possibility of application of FTIR in differentiation of malignant and benign breast lesions.
  • METHODS: FTIR spectra of surgically removed fresh breast tissues were measured by spectrometer equipped with mid-infrared fiber optics and an ATR probe.
  • Peaks in the spectra were measured and relative intensity ratios were calculated and analyzed if there are significant differences between the spectra of malignant and benign breast lesions.
  • RESULTS: There were significant differences (P < 0.05) between the spectra of malignant breast cancers and benign breast tissues in the relative intensity ratios of different peaks (I1640/ I1550 and I1160/I1120 for protein structures; I1640/I1460 and I1550/I1460 for relative content of protein and lipid; I1460/I1400 for lipid structures; I1310/I1240 for nucleic acid).
  • CONCLUSION: FTIR spectroscopy could be a useful tool in clinical diagnosis of breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis. Spectroscopy, Fourier Transform Infrared / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast / chemistry. Breast / pathology. Female. Humans. Lipids / analysis. Middle Aged. Neoplasm Proteins / analysis. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147115.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Lipids; 0 / Neoplasm Proteins
  •  go-up   go-down


6. Croce MV, Isla-Larrain M, Remes-Lenicov F, Colussi AG, Lacunza E, Kim KC, Gendler SJ, Segal-Eiras A: MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. Histol Histopathol; 2006 08;21(8):849-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue.
  • MATERIALS AND METHODS: We studied 163 breast and 89 colorectal cancer specimens, 10 breast and 14 colorectal benign conditions, and 12 breast and 20 colorectal normal samples.
  • From each tumor sample, subcellular fractions were obtained and analyzed by SDS-PAGE and WB.
  • RESULTS: By IHC, 146/163 (90%) and 151/163 (93%) of breast cancer were positive with CT33 and CT2, respectively; a statistically significant correlation was obtained (t=0.5199).
  • Seven out of ten (70%) benign breast specimens were positive with CT33 while all samples stained with CT2; in normal breast sample tissues, all were positive with both Abs.
  • In colorectal cancer samples, both antibodies stained 47/89 (53%) samples; CT2 reacted in 13/14 (93%) of benign samples while CT33 showed a positive reaction in 9/14 (64%) of benign specimens.
  • By WB, in breast and colorectal cancer samples, similar results were obtained with both antibodies: a main band at about 30kDa which represents the smaller subunit.
  • CONCLUSION: CT33 polyclonal antibody has demonstrated its efficacy to detect MUC1 in breast and colorectal cancer tissues with similar reactivity to CT2.
  • [MeSH-major] Antibodies, Monoclonal / metabolism. Breast Neoplasms / metabolism. Colorectal Neoplasms / metabolism. Mucin-1 / metabolism. Organic Cation Transport Proteins / metabolism
  • [MeSH-minor] Antibodies, Neoplasm / immunology. Antibodies, Neoplasm / metabolism. Biomarkers, Tumor. Breast / anatomy & histology. Breast / metabolism. Breast / pathology. Cell Fractionation. Colon / anatomy & histology. Colon / metabolism. Colon / pathology. Humans. Immunoenzyme Techniques. Rectum / anatomy & histology. Rectum / metabolism. Rectum / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691537.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / MUC-1 monoclonal antibody; 0 / Mucin-1; 0 / Organic Cation Transport Proteins; 0 / SLC22A16 protein, human
  •  go-up   go-down


7. Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR: B7-H4 overexpression in ovarian tumors. Gynecol Oncol; 2006 Jan;100(1):44-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B7-H4 overexpression in ovarian tumors.
  • This study was designed to evaluate the expression of B7-H4 protein, recently identified as a potential molecular marker of breast and ovarian cancer by quantitative PCR analysis, in benign tumors, tumors of low malignant potential and malignant tumors of the ovary.
  • METHODS: Archival formalin-fixed tissue blocks from serous, mucinous, endometrioid and clear cell ovarian tumors were evaluated by immunohistochemistry for the distribution of B7-H4 expression, and staining intensity was measured by automated image analysis.
  • The proportion of positive cells and median staining intensity was greater in serous carcinomas than in serous cystadenomas or serous tumors of low malignant potential, and the differences were statistically significant (P < 0.0001 and P = 0.034, respectively).
  • [MeSH-major] Antigens, CD80 / biosynthesis. Biomarkers, Tumor / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / immunology. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma, Endometrioid / immunology. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / immunology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. V-Set Domain-Containing T-Cell Activation Inhibitor 1

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16256178.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Biomarkers, Tumor; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


8. Shukla R, Pooja B, Radhika S, Nijhawan R, Rajwanshi A: Fine-needle aspiration cytology of extramammary neoplasms metastatic to the breast. Diagn Cytopathol; 2005 Apr;32(4):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytology of extramammary neoplasms metastatic to the breast.
  • Fine-needle aspiration (FNA) biopsy is the first-line investigation in any breast lump and hence cytomorphological recognition of nonmammary metastatic tumors to the breast and their distinction from primary tumors is important.
  • Metastatic breast neoplasms diagnosed over a 6-yr period from 1997 to 2002 were retrieved from the database of the Department of Cytopathology and the clinical, cytopathological, histochemical, and immunohistochemical findings were correlated with the histopathology of the primary tumor.
  • Fifteen cases of metastatic breast neoplasms were encountered constituting 1.47% of all malignant tumors of the breast diagnosed on FNA.
  • The preaspiration clinical diagnosis was either a benign breast lump or a malignancy (primary vs. metastatic).
  • The breast lump was the initial presentation in four cases and the cytodiagnosis of a metastatic malignancy lead to the subsequent detection of the primary malignancy.
  • The presence of unusual cytomorphological patterns on breast FNA should alert the cytopathologist to the possibility of a metastatic breast neoplasm, even if not suspected clinically.
  • A detailed history of the patient, clinical correlation, and immunocytochemistry helps in establishing an accurate diagnosis, which avoids unnecessary surgery and ensures appropriate treatment.
  • [MeSH-major] Breast / pathology. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / secondary
  • [MeSH-minor] Adolescent. Adult. Biopsy, Fine-Needle. Child. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15754368.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Abbate F, Bacigalupo L, Latronico A, Trentin C, Penco S, Menna S, Viale G, Cassano E, Bellomi M: Ultrasound-guided vacuum assisted breast biopsy in the assessment of C3 breast lesions by ultrasound-guided fine needle aspiration cytology: results and costs in comparison with surgery. Breast; 2009 Apr;18(2):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound-guided vacuum assisted breast biopsy in the assessment of C3 breast lesions by ultrasound-guided fine needle aspiration cytology: results and costs in comparison with surgery.
  • Breast lesions defined C3 at ultrasound (US)-guided fine needle aspiration cytology (FNAC) are probably benign, but exhibit atypias.
  • We evaluate the results of US-guided vacuum assisted breast biopsy (VABB) of these lesions.
  • VABB diagnosed: 17/138 (12.3%) malignant and 119/138 (86.2%) benign lesions.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Ultrasonography, Mammary / methods
  • [MeSH-minor] Biopsy, Fine-Needle / economics. Biopsy, Fine-Needle / methods. Cost-Benefit Analysis. Female. Humans. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity. Vacuum

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19342236.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


10. Giorgi Rossi P, Federici A, Farchi S, Chini F, Barca A, Guasticchi G, Borgia P: The effect of screening programmes on the treatment of benign breast neoplasms: observations from current practice in Italy. J Med Screen; 2006;13(3):123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of screening programmes on the treatment of benign breast neoplasms: observations from current practice in Italy.
  • In this study, we compare the incidences of treatments for benign and malignant neoplasms in the two groups.
  • We linked all incident cases of surgery for benign and malignant breast neoplasms, from the Hospital Information System (1999-2003) to the Mammographic Screening Information System (1999-2001).
  • We calculated incidence, adjusted for age and standardized breast cancer mortality ratio in each area of residence, for benign and malignant neoplasms surgery in non-yet-contacted and contacted woman.
  • RESULTS: The target population in Lazio is 681,000; 116,000 women were contacted during the study period and 3252 malignant and 1566 benign neoplasms were surgically treated.
  • Annual incidence was, respectively, 2.0/1000 and 1.1/1000 for malignant and benign neoplasms in women not contacted, and, respectively, 2.9/1000 and 1.1/1000 in the contacted population.
  • About one-half of the surgeries for benign neoplasms in compliant women were treated against the recommendation of the screening programme.
  • CONCLUSIONS: The implementation of the screening programme did not increase the incidence of treatment for benign neoplasms, and detected 50% more malignant neoplasms.
  • [MeSH-major] Breast Neoplasms / epidemiology. Mammography. Mass Screening. Patient Compliance / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007652.001).
  • [ISSN] 0969-1413
  • [Journal-full-title] Journal of medical screening
  • [ISO-abbreviation] J Med Screen
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Jordan SJ, Green AC, Whiteman DC, Webb PM, Australian Ovarian Cancer Study Group: Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol; 2007 Nov;107(2):223-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
  • OBJECTIVE: Some molecular and histological evidence suggests that mucinous epithelial ovarian cancers develop via a sequence from benign tumor through borderline tumor to invasive cancer.
  • Such a sequence would predict some shared risk factors between the different tumor types.
  • To investigate this, we examined risk factors for benign, borderline and invasive mucinous ovarian tumors.
  • Women with benign (n=133), borderline (n=147) and invasive (n=43) mucinous tumors of the ovary and women from the general population (n=1487) completed comprehensive health and lifestyle questionnaires.
  • RESULTS: Although parity was inversely related to risk of benign, borderline and invasive tumors, increasing numbers of births did not further decrease risk of any of the tumor types.
  • Hormonal contraceptives and breast-feeding were unrelated to risk.
  • However, 20 or more pack-years of smoking was associated with a more than twofold increase in risk of all three tumor types (OR=2.7, 95% CI 1.6-4.4 for benign tumors; OR=2.7, 95% CI 1.7-4.4 for borderline tumors; and OR=2.1, 95% CI 0.9-5.0 for invasive cancers) compared to never smoking.
  • Furthermore, patterns of risk factors across benign, borderline and invasive mucinous ovarian tumors are generally consistent with an adenoma-to-carcinoma sequence as the developmental pathway for this subtype of ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / etiology. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / etiology. Precancerous Conditions / epidemiology
  • [MeSH-minor] Adult. Aged. Australia. Case-Control Studies. Cell Transformation, Neoplastic / pathology. Female. Health Status. Humans. Life Style. Middle Aged. Neoplasm Invasiveness. Odds Ratio. Reproductive History. Risk Assessment. Risk Factors. Smoking / adverse effects. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662378.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


12. Roth FS, Felder JM, Friedman JD: Breast capsulectomy specimens and their clinical implications. Plast Reconstr Surg; 2010 Dec;126(6):1848-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast capsulectomy specimens and their clinical implications.
  • BACKGROUND: Plastic surgeons routinely submit breast capsulectomy surgical specimens for pathologic evaluation.
  • In an effort to reduce health care costs and the unnecessary use of hospital resources, this study reviews the efficacy of submitting breast capsulectomy specimens for pathologic examination.
  • METHODS: All patients from The Methodist Hospital in Houston, Texas, during the years 2000 to 2008 who underwent breast capsulectomy were selected for by Current Procedural Terminology codes 19370 and 19371 (open periprosthetic capsulotomy and periprosthetic capsulectomy of the breast, respectively).
  • RESULTS: The pathology reports of 434 capsulectomy specimens in 264 patients revealed benign capsules in 206 patients (78.0 percent).
  • One patient (0.4 percent) had carcinoma identified within a breast capsule.
  • Therefore, none of the 264 capsulectomy specimens revealed new neoplasms, occult disease, or other clinically significant findings that changed the patient's postoperative treatment.
  • CONCLUSIONS: No clinically significant findings were identified in this review of breast capsulectomy specimens in 264 patients.
  • In an effort to reduce health costs and the unnecessary use of hospital resources, breast capsulectomy specimens may not necessarily need to be routinely submitted for surgical pathologic evaluation.
  • [MeSH-major] Breast Diseases / pathology. Breast Diseases / surgery. Breast Implantation / economics. Calcinosis / pathology. Calcinosis / surgery. Foreign-Body Reaction / pathology. Foreign-Body Reaction / surgery. Granuloma, Foreign-Body / pathology. Granuloma, Foreign-Body / surgery. Pathology, Surgical / economics. Postoperative Complications / pathology. Postoperative Complications / surgery. Unnecessary Procedures / economics
  • [MeSH-minor] Breast / pathology. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Cost Savings. Female. Hospital Charges / statistics & numerical data. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Reoperation / economics. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21124126.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Elshof LE, Rutgers EJ, Deurloo EE, Loo CE, Wesseling J, Pengel KE, Gilhuijs KG: A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results. Breast Cancer Res Treat; 2010 Dec;124(3):707-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results.
  • Six-hundred-and-ninety consecutive patients with pathology-proven breast cancer planned for BCT based on clinical examination and conventional imaging underwent preoperative breast MRI.
  • Additional findings were pathology-proven or considered benign by follow-up.
  • Findings for which no pathology proof was available prior to surgery, were defined as Unidentified Breast Objects (UBOs).
  • None of the UBOs outside the primary tumour region resulted in malignant disease at follow-up after BCT (mean follow-up time: 57.1 months).
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Magnetic Resonance Imaging. Mastectomy, Segmental. Neoplasms, Multiple Primary
  • [MeSH-minor] Biopsy, Fine-Needle. Chi-Square Distribution. Contrast Media. Female. Humans. Neoplasm Staging. Netherlands. Patient Selection. Practice Guidelines as Topic. Predictive Value of Tests. Preoperative Care. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Breast Cancer Res Treat. 2010 Dec;124(3):717-21 [20803241.001]
  • (PMID = 20652399.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


14. de Lyra EC, da Silva IA, Katayama ML, Brentani MM, Nonogaki S, Góes JC, Folgueira MA: 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. J Steroid Biochem Mol Biol; 2006 Aug;100(4-5):184-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer.
  • 1,25(OH)2D3 is an antiproliferative agent that may inhibit proliferation of breast cancer (BC) cells in vitro and BC development in animals.
  • To unravel the role of Vitamin D3 in BC patients, we have investigated serum levels of 25(OH)D3 and its active form 1,25(OH)2D3 as well as tissue expression of 1alpha-hydroxylase, 24-hydroxylase, and Vitamin D-receptor (VDR), determined by semiquantitative RT-PCR, in 88 Brazilian BC patients and 35 women without cancer (submitted to mammoplasties or resection of benign lesions).
  • Our results indicate that 24-hydroxylase, VDR and 1alpha-hydroxylase mRNA tissue expression is similar in both groups and no correlation between 24-hydroxylase, 1alpha-hydroxylase, and VDR expression in breast tumors was found.
  • A low 1,25(OH)2D3 serum concentration seems to be associated to breast cancer, however, the mechanism involved in this regulation is still unclear.
  • [MeSH-major] 25-Hydroxyvitamin D3 1-alpha-Hydroxylase / metabolism. Breast / metabolism. Breast Neoplasms / metabolism. Calcifediol / blood. Calcitriol / blood. Receptors, Calcitriol / metabolism. Steroid Hydroxylases / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / metabolism. Brazil. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Regression Analysis. Vitamin D3 24-Hydroxylase

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16828283.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Calcitriol; EC 1.14.- / 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.126 / Vitamin D3 24-Hydroxylase; FXC9231JVH / Calcitriol; P6YZ13C99Q / Calcifediol
  •  go-up   go-down


15. Granić M, Oprić D, Pupić G, Babić D, Ivanović N, Nikolić D, Dikić S, Oprić S: [Surgical methods for the treatment of breast phyllodes tumors--a report of 319 cases]. Acta Chir Iugosl; 2006;53(1):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical methods for the treatment of breast phyllodes tumors--a report of 319 cases].
  • Breast phyllodes tumors (FT) belong the fibroapitelial group of breast tumors arising in terminal ductulo-lobular unit (TDLU).
  • Their incidence do not exceed 1% of all breast tumors.
  • Biologicaly they can be divided into benign, borderline and malignant group.
  • Incomplete tumor excision can be the reason for local reccurence.
  • METHODS: We analyzed histopathology features of 319 FT of the breast surgicaly removed on Departement of surgery Institut of oncology and radiology of Serbia between 1.1.1985.
  • -31.12.1994. Retrospective study of surgical treatment 84 patients with FT of the breast (69 benign, 4 borderline and 11 malignant) and 5 year follow up after surgery we analysed.
  • RESULTS: local reccurence after surgery was found in 17 (20,2 %) patients(14 benign , 2 borderline and 1 malignant FT), pulmonary metastases in 6 (7,1%) patients with malignant FT.
  • CONCLUSION: According to biological behavior we propose wide excision for benign and borderline forms and simple mastectomy for malignant FT, and voluminous benign and borderline forms.
  • [MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Female. Humans. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989148.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


16. Gast MC, van Dulken EJ, van Loenen TK, Kingma-Vegter F, Westerga J, Flohil CC, Knol JC, Jimenez CR, van Gils CH, Wessels LF, Schellens JH, Beijnen JH: Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. Int J Biol Markers; 2009 Jul-Sep;24(3):130-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling.
  • AIM: Novel diagnostic breast cancer markers have been extensively searched for in the proteome, using, among others, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS).
  • MATERIAL AND METHODS: We investigated breast cancer (n=75) and control (n=26) serum and tissue samples, collected prospectively by rigorous adherence to a strictly defined protocol.
  • RESULTS: Three serum peaks were significantly associated with breast cancer, while in tissue, 27 discriminative peaks were detected.
  • Several peak clusters gradually increased or decreased in intensity from healthy to benign to cancer, or with increasing cancer stage.
  • These are likely to have been generated by (breast) cancer-specific proteolytic activity in the tumor microenvironment.
  • CONCLUSIONS: These albumin fragment scan potentially provide insights into the pathophysiological mechanisms associated with, or underlying, breast cancer, and aid in improving breast cancer diagnosis.
  • [MeSH-major] Blood Proteins / analysis. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Aged. Diagnosis-Related Groups. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787623.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins
  •  go-up   go-down


17. Conway K, Parrish E, Edmiston SN, Tolbert D, Tse CK, Geradts J, Livasy CA, Singh H, Newman B, Millikan RC: The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res; 2005;7(6):R871-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study.
  • INTRODUCTION: Evidence suggests that alterations in estrogen signaling pathways, including estrogen receptor-alpha (ER-alpha), occur during breast cancer development.
  • This mutation was initially reported in one-third of hyperplastic benign breast lesions, although several recent studies failed to detect it in benign or malignant breast tissues.
  • METHODS: We screened 653 microdissected, newly diagnosed invasive breast tumors from patients in the Carolina Breast Cancer Study, a population-based case-control study of breast cancer in African American and white women in North Carolina, for the presence of the ER-alpha A908G mutation by using single-strand conformational polymorphism (SSCP) analysis and 33P-cycle sequencing.
  • RESULTS: We detected the ER-alpha A908G mutation in 37 of 653 (5.7%) breast tumors.
  • Three tumors exhibited only the mutant G base at nucleotide 908 on sequencing, indicating that the wild-type ER-alpha allele had been lost.
  • The ER-alpha A908G mutation was found more frequently in higher-grade breast tumors (odds ratio (OR) 2.83; 95% confidence interval (CI) 1.09 to 7.34, grade II compared with grade I), and in mixed lobular/ductal tumors (OR 2.10; 95% CI 0.86 to 5.12) compared with ductal carcinomas, although the latter finding was not statistically significant.
  • CONCLUSION: This population-based study, the largest so far to screen for the ER-alpha A908G mutation in breast cancer, confirms the presence of the mutant in invasive breast tumors.
  • The mutation was associated with higher tumor grade and mixed lobular/ductal breast tumor histology.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Steroid Biochem Mol Biol. 1999 Nov;71(1-2):21-7 [10619354.001]
  • [Cites] Breast Cancer Res Treat. 1999 Nov;58(1):31-9 [10634516.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7382-7 [10377423.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 1;27(5):1405-7 [9973633.001]
  • [Cites] Int J Oncol. 1998 Jun;12(6):1225-8 [9592178.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R113-8 [15642159.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9199-208 [15604293.001]
  • [Cites] Endocr Rev. 2004 Dec;25(6):869-98 [15583021.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):427-33 [10688862.001]
  • [Cites] Am J Epidemiol. 2000 Apr 1;151(7):703-14 [10752798.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4026-9 [10945602.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):733-6 [11072241.001]
  • [Cites] Breast Cancer. 2003;10(1):70-3 [12525766.001]
  • [Cites] Breast Cancer Res Treat. 2004 Apr;84(3):289-92 [15026626.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):51-4 [15034868.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):597-605 [15193262.001]
  • [Cites] Epidemiol Rev. 1993;15(1):17-35 [8405201.001]
  • [Cites] Breast Cancer Res Treat. 1995 Jul;35(1):51-60 [7612904.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2371-4 [9215322.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 15;25(22):4500-4 [9358158.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4258-65 [9398750.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Aug;62(5-6):363-72 [9449239.001]
  • (PMID = 16280033.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058223; United States / NCI NIH HHS / CA / 5-P50-CA58223
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Estrogen Receptor alpha
  • [Other-IDs] NLM/ PMC1410768
  •  go-up   go-down


18. Al Harthi B, Riaz MM, Al Khalaf AH, Al Zoum M, Al Shakweer W: Adrenal myelolipoma a rare benign tumour managed laparoscopically: Report of two cases. J Minim Access Surg; 2009 Oct;5(4):118-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal myelolipoma a rare benign tumour managed laparoscopically: Report of two cases.
  • Adrenal Myelolipoma is a rare benign neoplasm composed of mature adipose tissue and a variable amount of haemopoietic elements.
  • Two cases of myelolipoma are presented here, where the tumours were hormonally inactive, but presented with abdominal symptoms and were managed by laparoscopic adrenalectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1998 Jul;208(1):87-95 [9646797.001]
  • [Cites] J Urol. 1997 Apr;157(4):1213-6 [9120904.001]
  • [Cites] Surgery. 1973 May;73(5):665-70 [4697085.001]
  • [Cites] J Urol. 1992 Apr;147(4):1089-90 [1552592.001]
  • [Cites] Ir Med J. 2001 Sep;94(8):231-3 [11758622.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Apr;13(2):106-10 [12709616.001]
  • [Cites] J Urol. 1992 Jun;147(6):1478-81 [1593668.001]
  • (PMID = 20407573.001).
  • [ISSN] 1998-3921
  • [Journal-full-title] Journal of minimal access surgery
  • [ISO-abbreviation] J Minim Access Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2843128
  • [Keywords] NOTNLM ; Angiomyelolipoma / laparoscopic adrenalectomy / myelolipoma
  •  go-up   go-down


19. Djordjevic B, Hanna WM: Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon. Mod Pathol; 2008 Oct;21(10):1238-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon.
  • The expression of c-kit, a protooncogene tyrosine kinase receptor (CD117), in phyllodes tumors of the breast has been the subject of recent investigations.
  • We examined stromal c-kit expression by immunohistochemistry in 68 cases comprising fibroadenomas, fibroadenomas with cellular stroma, and benign, borderline, and malignant phyllodes tumors.
  • One borderline and one malignant phyllodes tumor showed a diffuse weak stromal signal, which could not be accounted for by toluidine blue and tryptase.
  • Our findings indicate that c-kit is an unlikely player in the pathogenesis of fibroepithelial lesions of the breast.
  • C-kit, therefore, has neither a diagnostic nor a prognostic role in phyllodes tumors, and there is no rationale for the treatment of recurrent of malignant phyllodes tumor patients with tyrosine kinase inhibitors.
  • [MeSH-major] Breast Neoplasms / metabolism. Mast Cells / metabolism. Phyllodes Tumor / metabolism. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Immunohistochemistry. Mastectomy. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500266.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


20. Sliwowska I, Kopczyński Z: [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer]. Wiad Lek; 2007;60(5-6):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
  • The aim of this study was to evaluate the zymography used to estimate gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of women with breast cancer.
  • MATERIAL AND METHODS: The study was conducted on the serum of 90 female with breast cancer aged 32-85 years (average 57.2 year) and in a group of 30 women with benign breast diseases aged 34-87 years (average 55.4 year).
  • RESULTS: The results showed significantly higher activity ofgelatinase A and gelatinase B in the group of women with breast cancer that in the control group.
  • Further analysis showed a strong correlation between activity of gelatinase A and B and advance stage of breast cancer, lymph node status, and tumour burden.
  • An elevated activity of gelatinases in patients with breast cancer confirms the role of these enzymes in the development of such tumours.
  • There was no significant difference in the gelatinases activity between the serum samples from patients with breast cancer and those from women with benign breast diseases.
  • The diagnostic accuracy of gelatinases evaluation is limited by the lack of sensitivity and specificity in early stage of the disease and in differentiation of breast cancer from benign diseases.
  • Measuring their activity in serum breast cancer patients indicates the patient's clinical condition.
  • A good correlation between serum activity of gelatinases and the prognostic factors suggest its usefulness as a marker both in the follow-up and in the prognosis of breast cancer patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / enzymology. Electrophoresis, Polyacrylamide Gel / methods. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood. Neoplasm Recurrence, Local / enzymology. Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Feasibility Studies. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966888.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


21. Shaker OG, Ay El-Deen MA, Abd El-Rahim MT, Talaat RM: Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients. Tumori; 2006 Nov-Dec;92(6):524-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients.
  • AIMS AND BACKGROUND: This study aims to detect the expression of E-selectin in tissue and the serum level of its soluble form in patients with primary breast cancer and benign breast tumors and to correlate the results with the clinicopathological data of the subjects.
  • Group A comprised 30 patients with primary breast cancer, group B 9 patients with benign breast tumors, and group C 11 healthy control women undergoing reduction mammoplasty.
  • E-selectin gene expression was investigated in breast tissues by PCR techniques and soluble E-selectin was measured in sera by ELISA.
  • It was expressed in 61.5% of patients with grade 2 breast cancer and in 82.4% of patients with grade 3 breast cancer.
  • E-selectin gene expression was detected in 60%, 73.3% and 100% of patients with stage II, III and IV tumors, respectively.
  • It was detected in 81.8% of patients with node-positive primary breast cancer and in 50% of patients with node-negative cancer.
  • E-selectin was found on the membranes of peritumoral endothelial cells while it was not found on breast epithelial cells.
  • They increased significantly with increasing breast cancer stage (P < 0.001) and were significantly higher in patients with lymph node involvement than in patients without node involvement (P < 0.001).
  • CONCLUSIONS: The studied marker showed associations with established prognostic parameters such as lymph node involvement and histological tumor grade.
  • E-selectin can be regarded as a promising strategy in improving tumor therapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. E-Selectin / metabolism. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Diseases / metabolism. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. In Situ Hybridization. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260494.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / E-Selectin
  •  go-up   go-down


22. Filipovski V, Banev S, Janevska V, Dukova B: Granular cell tumor of the breast: a case report and review of literature. Cases J; 2009;2:8551
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the breast: a case report and review of literature.
  • A 22-year-old female patient presented with a breast mass lesion with a clinical suspicion of a fibroadenoma.
  • Histological evaluation revealed a rare benign neoplasm - granular cell tumor.Granular cell tumor is rare neoplasm that may arise in virtually any body site, and in 5% it occurs in the breast.
  • The histogenesis of this tumor is still rather controversial and currently the most acceptable theory is a Schwann cell origin.
  • The main histological feature is granular cytoplasm of the tumor cells.From a clinical point of view there is a similarity between granular cell tumor and mammary carcinoma on mammography and ultrasound.
  • Pathohistologically, sometimes, differential diagnostic difficulties exist concerning apocrine carcinoma, histiocytic lesions and metastatic neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1992 Feb;116(2):206-8 [1733419.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;403(4):391-400 [6330972.001]
  • [Cites] Eur J Radiol. 1994 Nov;19(1):56-9 [7859762.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):709-11 [10782152.001]
  • [Cites] Cancer. 1953 Jul;6(4):786-9 [13059774.001]
  • [Cites] Obstet Gynecol. 1989 May;73(5 Pt 2):898-900 [2539575.001]
  • [Cites] Am J Clin Pathol. 1949 Jun;19(6):522-35 [18150636.001]
  • [Cites] J Surg Oncol. 1980;13(4):301-16 [6246310.001]
  • [Cites] South Med J. 1995 Nov;88(11):1146-8 [7481988.001]
  • [Cites] Diagn Cytopathol. 1996 Dec;15(5):403-8 [8989543.001]
  • [Cites] South Med J. 1997 Nov;90(11):1149-51 [9386062.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(4):333-4 [12214737.001]
  • [Cites] AMA Arch Pathol. 1955 Dec;60(6):663-8 [13268207.001]
  • [Cites] Arch Pathol Lab Med. 1988 Mar;112(3):302-3 [2830865.001]
  • (PMID = 19918386.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769456
  •  go-up   go-down


23. Koensgen D, Oskay-Oezcelik G, Katsares I, Walle U, Klapp C, Mustea A, Stengel D, Porzsolt F, Lichtenegger W, Sehouli J, Nord-Ostdeutschen Gesellschaft für Gynäkologische Onkologie (NOGGO) working group "Quality of life": Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study. Support Care Cancer; 2010 Aug;18(8):931-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the phase II study, the capability of BSCL-O was evaluated by questionnaire-guided interviews of 200 patients with primary OC, recurrent OC, metastasized breast cancer, and benign ovarian tumors.
  • [MeSH-major] Breast Neoplasms / psychology. Ovarian Neoplasms / psychology. Quality of Life. Surveys and Questionnaires
  • [MeSH-minor] Adult. Aged. Female. Germany. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1994;30A(9):1326-36 [7999421.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):579-86 [16446330.001]
  • [Cites] Semin Oncol. 1999 Feb;26(1 Suppl 1):32-9 [10071971.001]
  • [Cites] West J Nurs Res. 1997 Jun;19(3):334-50 [9170991.001]
  • [Cites] Oncology (Williston Park). 1994 Dec;8(12):21-5; discussion 25, 29-30 [7888309.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1809-17 [11251013.001]
  • [Cites] Anticancer Res. 2009 Jul;29(7):2831-6 [19596970.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Nov;19(11):1633-7 [6315445.001]
  • [Cites] J Obstet Gynaecol Can. 2004 Jul;26(7):627-31 [15248931.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 2):S151-5 [7530679.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5605-12 [16110020.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(1):47-53 [11165129.001]
  • [Cites] Support Care Cancer. 2005 Apr;13(4):219-27 [15538640.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):907-15 [8039118.001]
  • [Cites] Gynecol Oncol. 1993 Aug;50(2):202-7 [8397153.001]
  • [Cites] Support Care Cancer. 1996 May;4(3):169-79 [8739648.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(10):1402-8 [12826043.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):741-8 [14675309.001]
  • [Cites] Eur J Cancer. 1990 Mar;26(3):345-52 [2141492.001]
  • (PMID = 19760286.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Soares Leite D, Lima de Lima PD, Ferreira Leal M, Suchi Chen E, Casartelli C, de Arruda Cardoso Smith M, Rodríguez Burbano R: Investigation of chromosome 21 aneuploidies in breast fibroadenomas by fluorescence in situ hybridisation. Clin Exp Med; 2006 Dec;6(4):166-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of chromosome 21 aneuploidies in breast fibroadenomas by fluorescence in situ hybridisation.
  • Fibroadenoma (FA) is a benign breast tumour that occurs in about 25% of women.
  • Cytogenetic studies suggest that numerical chromosomal aberrations may contribute to tumorigenesis, but chromosomal instability is still poorly characterised in breast cancer.
  • The aim of this study was to investigate numerical alterations of chromosome 21 in 15 breast FAs.
  • Classical cytogenetics analysis showed that all cells were diploidies with modal number varying between 43 and 47 chromosomes, and clonal chromosome alterations in 46.7% of tumours.
  • The study of benign proliferations and comparison with chromosome alterations in their malignant counterparts should result in an understanding of the genes acting in cell proliferation alone and those that cause these cells to both undergo malignant transformation and become invasive.
  • [MeSH-major] Aneuploidy. Breast Neoplasms / genetics. Chromosomes, Human, Pair 21 / genetics. Fibroadenoma / genetics. In Situ Hybridization, Fluorescence

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17191108.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


25. Nassar A, Cohen C, Cotsonis G, Carlson G: Significance of intramammary lymph nodes in the staging of breast cancer: correlation with tumor characteristics and outcome. Breast J; 2008 Mar-Apr;14(2):147-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of intramammary lymph nodes in the staging of breast cancer: correlation with tumor characteristics and outcome.
  • Intramammary lymph nodes (intraMLNs) have received little attention as potential prognostic indicators for patients with breast carcinoma.
  • Patients with stage I breast carcinoma and positive intraMLN metastases have been reported to have a poorer prognosis compared to patients with similar stage and negative intraMLN metastases.
  • However, the presence of intraMLN metastases does not appear to influence the survival of patients with stage II breast carcinoma.
  • In the current retrospective analysis, we assessed the clinical significance of intraMLNs and evaluated their role in predicting outcome in patients with breast carcinoma.
  • In all, 59 patients (50.8%) were found in association with benign breast conditions and the remaining 57 (49.2%) with primary breast carcinoma.
  • Primary tumor characteristics and axillary lymph node (AxLN) status were recorded.
  • Statistical analysis was performed to detect correlation between intraMLN and tumor characteristics as well as outcome.
  • Univariate analysis revealed that predictors of intraMLN metastases include: tumor size (p = 0.04), tumor grade (p = 0.04), tumor stage (p < 0.001), and AxLN status (p < 0.001).
  • IntraMLN metastasis is a poor prognostic marker but not an independent predictor of poor outcome in patients with breast carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Lymph Nodes. Mammary Glands, Human / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248563.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Diebold T, Jacobi V, Scholz B, Hensel C, Solbach C, Kaufmann M, Viana F, Balzer J, Peters J, Vogl T: Value of electrical impedance scanning (EIS) in the evaluation of BI-RADS III/IV/V-lesions. Technol Cancer Res Treat; 2005 Feb;4(1):93-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The evaluation included a scaling of lesions from 1 (surely benign) up to 5 (highly suggestive for malignancy) as well as the additional notification of spots.
  • Histology revealed benign results in 138 lesions and malignant results in 118 lesions (DCIS=61, ID-Ca=51, IL-Ca=5, mucinous Ca=1).
  • There were significant differences of the sensitivity of EIS regarding the tumor size.
  • [MeSH-major] Breast Neoplasms / pathology. Imaging, Three-Dimensional / instrumentation. Imaging, Three-Dimensional / methods. Mammography / instrumentation. Mammography / methods
  • [MeSH-minor] Electric Impedance. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15649092.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Nonomura K, Shimamoto K, Hatasa K, Mizuno M, Machida K, Mizuno H, Tanaka H, Sakakibara S: Differential diagnosis of breast mass image-forming lesions based on changes in depth-width ratio and internal echo intensity by hand-held probe compression. J Med Ultrason (2001); 2008 Jun;35(2):63-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of breast mass image-forming lesions based on changes in depth-width ratio and internal echo intensity by hand-held probe compression.
  • PURPOSE: Regarding mass image-forming lesions, the 2005 Guidelines for Ultrasonic Diagnosis of Breast Diseases, published by the Japan Society of Ultrasonics in Medicine (JSUM), includes the evaluation of tumor compressibility, which is visually assessed by the degree of deformation caused by applying external pressure to the tumor.
  • However, this is only a subjective estimation under real-time observation; consequently, quantitative evaluation of tumor deformation and the percentage change in internal echo intensity was attempted based on changes in the depth-width ratio and in the internal echo intensity on hand-held probe compression.
  • We evaluated the usefulness of these measurements in the differential diagnosis of benign and malignant tumors.
  • METHODS: The subjects were 139 patients (89 benign and 50 malignant cases) who underwent breast ultrasonography with a 10-MHz (from 4-to 10-MHz) linear probe.
  • The deformation index (D.I.) of the tumor was defined as: [1 - (depth-width ratio with 3.0 ± 0.6-kg-weighted compression)/(depth-width ratio without compression)] × 100 (%).
  • RESULTS: There was a significant difference in the D.I. between benign lesions (35.5% ± 14.7%) and malignant lesions (15.4% ± 6.2%) (P < 0.001).
  • The cut-off ratio in differentiating benign from malignant lesions was approximately 25%.
  • The rate of change in echo intensity of benign lesions (149.7% ± 34.3%) was significantly higher than that of malignant lesions (122.9% ± 19.9%) (P < 0.001).
  • CONCLUSION: Using an electronic linear probe, quantitative indexes including the D.I. and the rate of change in internal echo intensity could be obtained with the help of a weight meter, and could prove effective for the differential diagnosis of breast mass-image forming lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrason Imaging. 1998 Oct;20(4):260-74 [10197347.001]
  • [Cites] Ultrasound Med Biol. 1988;14 Suppl 1:53-7 [3055603.001]
  • [Cites] Ultrasound Obstet Gynecol. 2006 Sep;28(3):335-40 [16909438.001]
  • [Cites] Radiology. 2006 May;239(2):341-50 [16484352.001]
  • [Cites] J Med Ultrason (2001). 2005 Sep;32(3):127-9 [27277270.001]
  • [Cites] Nihon Hoshasen Gijutsu Gakkai Zasshi. 2005 Jun 20;61(6):811-6 [15995610.001]
  • [Cites] Eur J Ultrasound. 1998 Sep;8(1):25-31 [9795006.001]
  • (PMID = 27278693.001).
  • [ISSN] 1346-4523
  • [Journal-full-title] Journal of medical ultrasonics (2001)
  • [ISO-abbreviation] J Med Ultrason (2001)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; breast neoplasm / deformation index / mammary / tissue characterization / ultrasonography
  •  go-up   go-down


28. Sisci D, Morelli C, Garofalo C, Romeo F, Morabito L, Casaburi F, Middea E, Cascio S, Brunelli E, Andò S, Surmacz E: Expression of nuclear insulin receptor substrate 1 in breast cancer. J Clin Pathol; 2007 Jun;60(6):633-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of nuclear insulin receptor substrate 1 in breast cancer.
  • BACKGROUND: Insulin receptor substrate 1 (IRS-1), a cytoplasmic protein transmitting signals from the insulin and insulin-like growth factor 1 receptors, has been implicated in breast cancer.
  • However, the expression of nuclear IRS-1 in breast cancer biopsy specimens has never been examined.
  • AIMS: To assess whether nuclear IRS-1 is present in breast cancer and non-cancer mammary epithelium, and whether it correlates with other markers, especially ERalpha.
  • RESULTS: Median nuclear IRS-1 expression was found to be low in normal mammary epithelial cells (1.6%) and high in benign tumours (20.5%), ductal grade 2 carcinoma (11.0%) and lobular carcinoma (approximately 30%).
  • Median ERalpha expression in normal epithelium, benign tumours, ductal cancer grade 2 and 3, and lobular cancer grade 2 and 3 were 10.5, 20.5, 65.0, 0.0, 80 and 15%, respectively.
  • Nuclear IRS-1 and ERalpha positively correlated in ductal cancer (p<0.001) and benign tumours (p<0.01), but were not associated in lobular cancer and normal mammary epithelium.
  • In ductal carcinoma, both nuclear IRS-1 and ERalpha negatively correlated with tumour grade, size, mitotic index and lymph node involvement.
  • CONCLUSIONS: A positive association between nuclear IRS-1 and ERalpha is a characteristic for ductal breast cancer and marks a more differentiated, non-metastatic phenotype.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Cell Nucleus / metabolism. Phosphoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Cytoplasm / metabolism. Estrogen Receptor alpha / metabolism. Female. Humans. Immunoenzyme Techniques. Insulin Receptor Substrate Proteins. Mammary Glands, Human / metabolism. Microscopy, Confocal. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9817-24 [11139588.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):35-46 [15965906.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6747-54 [11559546.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):197-209 [11566611.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 2;288(3):685-9 [11676497.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):17231-8 [11877394.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):32078-85 [12063262.001]
  • [Cites] J Cell Physiol. 2003 Feb;194(2):108-16 [12494449.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4007-16 [12821935.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6589-97 [14528284.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):873-7 [14601044.001]
  • [Cites] Metabolism. 2003 Dec;52(12):1606-11 [14669164.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):794-801 [14710360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9272-6 [15197263.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7517-26 [15318176.001]
  • [Cites] J Clin Invest. 1973 Jan;52(1):73-7 [4345203.001]
  • [Cites] Monogr Pathol. 1984;(25):149-74 [6377047.001]
  • [Cites] Bull Cancer. 1989;76(3):311-9 [2544239.001]
  • [Cites] Clin Chem. 1993 Jun;39(6):1345-6 [7684958.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3736-40 [8339284.001]
  • [Cites] Eur J Cancer. 1994;30A(3):307-11 [8204350.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):381-400 [8004612.001]
  • [Cites] Trends Biochem Sci. 1994 Jul;19(7):289-93 [8048169.001]
  • [Cites] J Cell Biochem. 2000 Jan;76(4):605-14 [10653980.001]
  • [Cites] J Biol Chem. 2000 Apr 28;275(17):12565-71 [10777546.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):95-105 [10791772.001]
  • [Cites] Prev Vet Med. 2000 May 30;45(1-2):23-41 [10802332.001]
  • [Cites] Heart. 2000 Jul;84(1):71-8 [10862595.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):506-13 [11102895.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5574-81 [11114737.001]
  • [Cites] Breast Cancer Res Treat. 1994;32(1):85-95 [7529598.001]
  • [Cites] Science. 1995 Dec 1;270(5241):1491-4 [7491495.001]
  • [Cites] Endocrinology. 1996 May;137(5):1735-44 [8612509.001]
  • [Cites] EMBO J. 1996 Mar 15;15(6):1292-300 [8635462.001]
  • [Cites] Ann N Y Acad Sci. 1996 Apr 30;784:189-201 [8651569.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:615-58 [8725404.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2606-10 [9205064.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3079-83 [9242428.001]
  • [Cites] Diabetologia. 1997 Jul;40 Suppl 2:S2-17 [9248696.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):828-34 [9311601.001]
  • [Cites] J Pathol. 1997 Dec;183(4):412-7 [9496257.001]
  • [Cites] Breast Cancer Res Treat. 1998 Feb;47(3):295-302 [9516083.001]
  • [Cites] Recent Prog Horm Res. 1998;53:119-38 [9769706.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1429-36 [9815941.001]
  • [Cites] Clin Cancer Res. 1996 Dec;2(12):2037-42 [9816164.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):103-9 [9815544.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Dec 18;253(2):315-9 [9878535.001]
  • [Cites] Recent Results Cancer Res. 1998;152:63-70 [9928547.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):299-304 [10188734.001]
  • [Cites] Mol Endocrinol. 1999 May;13(5):787-96 [10319328.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Sep;23(3):385-94 [15595626.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):645-9 [15917419.001]
  • [Cites] J Biol Chem. 2005 Aug 19;280(33):29912-20 [15967802.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2545-54 [11489838.001]
  • (PMID = 16882697.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Neoplasm Proteins; 0 / Phosphoproteins
  • [Other-IDs] NLM/ PMC1955087
  •  go-up   go-down


29. Akin M, Irkorucu O, Koksal H, Gonul II, Gultekin S, Kurukahvecioglu O, Anadol AZ, Tekin E: Phyllodes tumor of the breast; a case series. Bratisl Lek Listy; 2010;111(5):271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor of the breast; a case series.
  • BACKGROUND: Phyllodes tumor (PT) is a rare neoplasm comprising less than 1% of all breast tumors.
  • Its clinical spectrum ranges from a benign and locally recurrent form of behavior to malignant and metastatic forms.
  • All cases were histologically examined by an experienced breast pathologist, and tumors were classified as benign, borderline malignant or malignant according to standard histological criteria.
  • RESULTS: The median age at diagnosis was 45.5 years (range: 21-69 years).
  • Seven (70%) of 10 tumors were benign and 3 (30%) were malignant.
  • The median tumor size was 29 mm (range: 12-80 mm).
  • CONCLUSION: PT is a rare neoplasm of the breast.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568416.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


30. Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B: Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol; 2005 Nov;33(5):332-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant mesothelioma (MM) is a locally aggressive and highly lethal tumor of serosal cavities that is rarely associated with clinically detectable metastasis to distant organs.
  • Effusions from patients diagnosed with ovarian (=24) and breast (=38) adenocarcinomas and MM (=24) (total = 86) were analyzed for 67-kd LR protein expression, using immunocytochemistry.
  • Protein expression of the 67-kd LR was frequently detected in carcinomas (19/24 ovarian tumors, 79%; 15/38 breast tumors, 39%), but was rare in MM (2/24 cases, 8%), despite the presence of mRNA transcripts for the receptor in all 21 specimens studied using RT-PCR.
  • Nine benign effusions that were additionally studied for protein expression were uniformly negative, as were all reactive mesothelial cells in malignant effusions.
  • Our results suggest that the 67-kd LR may aid in the differential diagnosis between metastatic carcinoma, mainly of ovarian origin, and MM.
  • They additionally suggest that the failure of MM to express the 67-kd LR protein, as opposed to the frequent expression in carcinomas with proven metastatic capacity, may be one of the factors contributing to the reduced ability of the former tumor to metastasize to distant organs.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Female. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16240397.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Laminin
  •  go-up   go-down


31. Kuhl CK, Schrading S, Weigel S, Nüssle-Kügele K, Sittek H, Arand B, Morakkabati N, Leutner C, Tombach B, Nordhoff D, Perlet C, Rieber A, Heindel W, Brambs HJ, Schild H: [The "EVA" Trial: Evaluation of the Efficacy of Diagnostic Methods (Mammography, Ultrasound, MRI) in the secondary and tertiary prevention of familial breast cancer. Preliminary results after the first half of the study period]. Rofo; 2005 Jun;177(6):818-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The "EVA" Trial: Evaluation of the Efficacy of Diagnostic Methods (Mammography, Ultrasound, MRI) in the secondary and tertiary prevention of familial breast cancer. Preliminary results after the first half of the study period].
  • [Transliterated title] Die "EVA"-Studie: Evaluierung der Leistungsfähigkeit diagnostischer Verfahren (Mammographie, Sonographie, MRT) zur sekundären und tertiären Prävention des familiären Mammakarzinoms -- Zwischenergebnisse nach der ersten Hälfte der Förderungsperiode.
  • PURPOSE: To investigate the respective diagnostic accuracies of the different breast imaging modalities, i. e., mammography (Mx), high-frequency breast ultrasound (US), and dynamic contrast-enhanced breast (MRI) regarding the early diagnosis of familial (hereditary) breast cancer.
  • The protocol consists of semiannual clinical visits and breast ultrasound, and annual bilateral two-view Mx, US and MRI.
  • A total of 12 breast cancers have been identified, with 11/12 cases in the pTis or pT1/N0 stage.
  • A total of 19 benign lesions were biopsied due to false-positive imaging diagnoses.
  • The breast cancer detection rates were: Mx: 5/12 (42 %), US 3/12 (25 %), MRI 10/12 (83 %), and the positive predictive values: Mx 5/17 (29 %), US 3/15 (30 %), and MRI 10/23 (43 %).
  • CONCLUSION: The preliminary data suggest that early diagnosis of familial breast cancer is feasible by intensified surveillance, in particular with the addition of MRI.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging. Mammography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Biopsy. Breast / pathology. False Positive Reactions. Female. Follow-Up Studies. Genetic Predisposition to Disease. Germany. Humans. Middle Aged. Neoplasm Staging. Prospective Studies. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902631.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


32. Buch A, Rout P, Makhija P: Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump. Indian J Pathol Microbiol; 2006 Apr;49(2):259-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump.
  • An unusual combination of two benign breast neoplasms adenomyoepithelioma and phyllodes tumor presenting as a solitary breast lump have been described.
  • Both these tumors have tendencies to recur and have malignant potential.
  • This patient also presented with a recurrent breast neoplasm.
  • [MeSH-major] Adenomyoma / pathology. Breast Neoplasms / pathology. Myoepithelioma / pathology. Neoplasms, Multiple Primary / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Indian J Pathol Microbiol. 2006 Jul;49(3):476
  • (PMID = 16933731.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


33. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N: Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol; 2008;9:76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer.
  • While ECs have been validated for quantification of mRNA expression in various experimental settings, to date there is no report of the validation of miRNA ECs for expression profiling in breast tissue.
  • In this study, the expression of five miRNA genes (let-7a, miR-10b, miR-16, miR-21 and miR-26b) and three small nucleolar RNA genes (RNU19, RNU48 and Z30) was examined across malignant, benign and normal breast tissues to determine the most appropriate normalisation strategy.
  • This is the first study to identify reliable ECs for analysis of miRNA by RQ-PCR in human breast tissue.
  • [MeSH-major] Breast Neoplasms / genetics. Gene Expression Profiling / standards. Gene Expression Regulation, Neoplastic. MicroRNAs / genetics
  • [MeSH-minor] Female. Gene Silencing. Genes, Neoplasm. Humans. Polymerase Chain Reaction / standards. RNA, Small Nuclear / genetics. Reference Standards

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2005 Dec 15;14(24):3813-21 [16239240.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Nucleic Acids Res. 2006;34(2):e9 [16434699.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 28;343(1):85-9 [16529715.001]
  • [Cites] J Urol. 2006 May;175(5):1915-20 [16600798.001]
  • [Cites] Mol Cancer. 2006;5:24 [16784538.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6188-96 [17028598.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(5):1859-67 [17194750.001]
  • [Cites] Am J Obstet Gynecol. 2007 Mar;196(3):261.e1-6 [17346547.001]
  • [Cites] Nat Protoc. 2006;1(3):1559-82 [17406449.001]
  • [Cites] BMC Genomics. 2007;8:166 [17565689.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 23;363(3):542-6 [17889832.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Nature. 2008 Jan 10;451(7175):147-52 [18185580.001]
  • [Cites] BMC Mol Biol. 2007;8:107 [18042273.001]
  • [Cites] Nat Cell Biol. 2008 Feb;10(2):202-10 [18193036.001]
  • [Cites] Breast Cancer Res. 2007;9(6):R76 [17980029.001]
  • [Cites] Hepatology. 2008 Mar;47(3):897-907 [18176954.001]
  • [Cites] RNA. 2008 May;14(5):844-52 [18375788.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13967-73 [10788523.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] J Biochem Biophys Methods. 2000 Nov 20;46(1-2):69-81 [11086195.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14311-6 [11106375.001]
  • [Cites] EMBO Rep. 2001 Nov;2(11):986-91 [11713189.001]
  • [Cites] Hum Mol Genet. 2001 Nov 1;10(23):2687-700 [11726556.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):894-902 [11842100.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(19):6663-8 [12215523.001]
  • [Cites] Anal Biochem. 2002 Oct 15;309(2):293-300 [12413463.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Cancer Lett. 2003 Mar 20;192(1):1-17 [12637148.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Bioessays. 2003 Oct;25(10):930-9 [14505360.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11 [14681370.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Genome Biol. 2004;5(3):R13 [15003116.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9740-4 [15210942.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] J Biomol Tech. 2004 Sep;15(3):155-66 [15331581.001]
  • [Cites] Genome Biol. 2004;5(9):R68 [15345052.001]
  • [Cites] In Vitro Cell Dev Biol. 1987 Aug;23(8):585-90 [3114226.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5616-9 [3664468.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1391-400 [8657112.001]
  • [Cites] BMC Dev Biol. 2005;5:27 [16324220.001]
  • [Cites] Cell. 1997 May 30;89(5):799-809 [9182768.001]
  • [Cites] Nucleic Acids Res. 1998 Apr 1;26(7):1576-87 [9512526.001]
  • [Cites] RNA. 1998 Apr;4(4):445-54 [9630250.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6906-17 [10490628.001]
  • [Cites] Anal Biochem. 2004 Dec 1;335(1):1-9 [15519565.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Biotechniques. 2005 Jul;39(1):75-85 [16060372.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7376-83 [16243810.001]
  • [Cites] RNA. 2005 Nov;11(11):1737-44 [16244135.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • (PMID = 18718003.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Small Nuclear
  • [Other-IDs] NLM/ PMC2533012
  •  go-up   go-down


34. Bereznaya NM, Kirnasovskaya EA, Vinnichuk YD, Belova OB, Lukyanova NY: Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol; 2008 Dec;30(4):295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors.
  • AIM: To study the expression of CD40 by cells of benign and malignant tumors of mammary gland, and to compare the efficacy of lymphocytes antitumor activity against drug resistant and sensitive breast tumors in relevance to CD40 expression.
  • METHODS: Breast tumor explants were cultured with autologous lymphocytes in double diffusion chambers.
  • Expression level of molecules on tumor cells was analyzed using immunohistochemical method (paraffin embedded slides), and on lymphocytes - by the method of indirect immunofluorescence.
  • RESULTS: The highest level of CD40 expression was detected on cells of chemoresistant malignant breast tumors, and the lowest one - on cells of benign breast tumors.
  • The decreased CD40 expression on lymphocytes from patients with drug resistant breast cancer was compared with that on lymphocytes of the patients with drug sensitive breast cancer.
  • The study of antitumor activity of autologous lymphokine activated killer cells (LAK) has shown their pronounced antitumor activity against drug resistant malignant breast tumors.
  • CONCLUSION: Marked antitumor activity of LAK from the patients with drug resistant breast cancer is associated with high expression level of CD40 on tumor cells and with its decreased expression on lymphocytes.
  • [MeSH-major] Antigens, CD40 / biosynthesis. Breast Neoplasms / immunology. Drug Resistance, Neoplasm / immunology. Killer Cells, Lymphokine-Activated / immunology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112427.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antigens, CD40; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


35. Chen YW, Chuang YW, Lai YC, Hsieh JS, Liu GC, Hou MF: Is early dynamic lymphoscintigraphy for detection of sentinel lymph nodes always achievable in breast tumor? Ann Nucl Med; 2006 Jan;20(1):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is early dynamic lymphoscintigraphy for detection of sentinel lymph nodes always achievable in breast tumor?
  • OBJECTIVE: In this article, we will discuss the achievement of early dynamic lymphoscintigraphic protocol and compare detection of sentinel node between benign and malignant breast tumors, and whether pathologic factor is related or not.
  • The average age of patients was 47.6 +/- 9.8 years and all of them were clinically suspected of having breast cancer.
  • The average tumor was 2.1 +/- 1.1 cm in size.
  • All patients underwent surgery sixteen to twenty hours later and had a final pathological diagnosis.
  • From the summation image of dynamic study, identified axillary sentinel nodal activity was found as 80% in the group of benign breast tumor, but only 48% in the group of malignant breast tumor.
  • However, this short period of protocol is not always achievable to detect sentinel node, especially in the group with breast malignant lesions.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Breast Neoplasms / secondary. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Sentinel Lymph Node Biopsy / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485574.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


36. Nielsen BS, Egeblad M, Rank F, Askautrud HA, Pennington CJ, Pedersen TX, Christensen IJ, Edwards DR, Werb Z, Lund LR: Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression. PLoS One; 2008 Aug 13;3(8):e2959
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression.
  • Matrix metalloproteinase (MMP) 13 (collagenase 3) is an extracellular matrix remodeling enzyme that is induced in myofibroblasts during the earliest invasive stages of human breast carcinoma, suggesting that it is involved in tumor progression.
  • As in human tumors, Mmp13 mRNA was found in myofibroblasts of invasive grade II and III carcinomas, but not in benign grade I and II mammary intraepithelial neoplasias.
  • To determine if MMP13 plays a role in tumor progression, we crossed MMTV-PyMT mice with Mmp13 deficient mice.
  • The absence of MMP13 did not influence tumor growth, vascularization, progression to more advanced tumor stages, or metastasis to the lungs, and the absence of MMP13 was not compensated for by expression of other MMPs or tissue inhibitor of metalloproteinases.
  • However, an increased fraction of thin collagen fibrils was identified in MMTV-PyMT;Mmp13(-/-) compared to MMTV-PyMT;Mmp13(+/+) tumors, showing that collagen metabolism was altered in the absence of MMP13.
  • We conclude that the expression pattern of Mmp13 mRNA in myofibroblasts of invasive carcinomas in the MMTV-PyMT breast cancer model recapitulates the expression pattern observed in human breast cancer.
  • Our results suggest that MMP13 is a marker of carcinoma-associated myofibroblasts of invasive carcinoma, even though it does not make a major contribution to tumor progression in the MMTV-PyMT breast cancer model.
  • [MeSH-major] Antigens, Polyomavirus Transforming / pharmacology. Fibroblasts / enzymology. Fibroblasts / virology. Mammary Neoplasms, Animal / enzymology. Mammary Neoplasms, Animal / pathology. Matrix Metalloproteinase 13 / biosynthesis
  • [MeSH-minor] Animals. DNA Primers. Disease Progression. Female. Lung Neoplasms / blood supply. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Mice. Mice, Knockout. Neoplasm Metastasis. Neoplasm Staging. Neovascularization, Pathologic

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17192-7 [15563592.001]
  • [Cites] Nucleic Acids Res. 1991 Aug 11;19(15):4293 [1870982.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1233-40 [15760918.001]
  • [Cites] Oncogene. 2005 Jul 28;24(32):5053-68 [15856015.001]
  • [Cites] Circulation. 2005 Oct 25;112(17):2708-15 [16230484.001]
  • [Cites] J Invest Dermatol. 2006 Feb;126(2):486-96 [16374453.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):9-34 [16680569.001]
  • [Cites] Int J Exp Pathol. 2006 Oct;87(5):383-91 [16965566.001]
  • [Cites] Dev Biol. 2006 Nov 1;299(1):164-75 [16949567.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):50-9 [17200706.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 23;354(4):846-51 [17275784.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2086-95 [17290405.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2007 Mar;12(1):83-97 [17286208.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):800-8 [17851543.001]
  • [Cites] PLoS One. 2007;2(11):e1150 [17987127.001]
  • [Cites] Cancer Biol Ther. 2007 Apr;6(4):618-9 [18027438.001]
  • [Cites] Nat Cell Biol. 2007 Dec;9(12):1392-400 [18037882.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):141-52 [18242514.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1378-87 [18316601.001]
  • [Cites] Oncogene. 2008 May 22;27(23):3274-81 [18071307.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):883-7 [10706099.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1997-2003 [11395377.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7091-100 [11585740.001]
  • [Cites] Lab Invest. 2001 Nov;81(11):1485-501 [11706057.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8298-305 [11719463.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):333-45 [12651907.001]
  • [Cites] Oncogene. 2003 Jun 19;22(25):3964-76 [12813470.001]
  • [Cites] Aging Cell. 2002 Oct;1(1):57-65 [12882354.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):1-10 [12925950.001]
  • [Cites] J Cell Biol. 2003 Sep 15;162(6):1123-33 [12975354.001]
  • [Cites] Cytokine. 2003 Oct;24(1-2):25-35 [14561488.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1887-99 [14578188.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):2113-26 [14578209.001]
  • [Cites] J Neurosci. 2003 Nov 5;23(31):10107-15 [14602826.001]
  • [Cites] Histochem J. 1979 Jul;11(4):447-55 [91593.001]
  • [Cites] Int J Cancer. 1988 May 15;41(5):707-12 [2835323.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):954-61 [1312220.001]
  • [Cites] Cell Tissue Res. 1992 Apr;268(1):167-77 [1499048.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16766-73 [8207000.001]
  • [Cites] Semin Cancer Biol. 1995 Jun;6(3):165-73 [7495985.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1544-50 [8576151.001]
  • [Cites] FEBS Lett. 1996 Feb 12;380(1-2):17-20 [8603731.001]
  • [Cites] J Biol Chem. 1996 Jul 19;271(29):17124-31 [8663255.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7608-16 [9065415.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4882-8 [9354453.001]
  • [Cites] Biochem J. 1998 Apr 15;331 ( Pt 2):453-8 [9531484.001]
  • [Cites] Oncogene. 1998 Jun 18;16(24):3097-104 [9671388.001]
  • [Cites] EMBO J. 1999 Sep 1;18(17):4645-56 [10469644.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Development. 2004 Dec;131(23):5883-95 [15539485.001]
  • [Cites] Histochemistry. 1989;93(1):27-9 [2482274.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • (PMID = 18698413.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA057621; United Kingdom / Medical Research Council / / G0100250; United States / NCI NIH HHS / CA / CA072006; United States / NCI NIH HHS / CA / R01 CA057621; United States / NCI NIH HHS / CA / P01 CA072006
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / DNA Primers; EC 3.4.24.- / Matrix Metalloproteinase 13
  • [Other-IDs] NLM/ PMC2493034
  •  go-up   go-down


37. Dillon MF, Hill AD, Quinn CM, O'Doherty A, McDermott EW, O'Higgins N: The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases. Ann Surg; 2005 Nov;242(5):701-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases.
  • OBJECTIVE: Preoperative core biopsy in breast cancer is becoming the standard of care.
  • METHODS: All patients undergoing core biopsy for breast abnormalities over a 5-year period (1999-2003) were reviewed.
  • The accuracy rates for each method of core biopsy, the histologic agreement between the core pathology and subsequent excision pathology, and the length of follow-up for cases of benign disease were studied.
  • Patients whose biopsies were benign but who were subsequently diagnosed with cancer underwent detailed review.
  • RESULTS: There were 2427 core biopsies performed over the 5-year period, resulting in a final diagnosis of cancer in 1384 patients, benign disease in 954 patients, and atypical disease in 89 patients.
  • False-negative biopsies occurred in 85 patients, and in 8 of these patients the diagnosis was delayed by greater than 2 months.
  • CONCLUSION: Ultrasound guidance should be used to perform core biopsies in evaluating all breast abnormalities visible on ultrasound.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Breast Diseases / pathology. Breast Diseases / ultrasonography. Cohort Studies. Diagnosis, Differential. False Negative Reactions. Female. Follow-Up Studies. Humans. Immunohistochemistry. Incidence. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Dec 15;89(12):2538-46 [11135213.001]
  • [Cites] Radiology. 1999 Mar;210(3):799-805 [10207484.001]
  • [Cites] Cancer. 2001 Apr 25;93(2):146-50 [11309781.001]
  • [Cites] Ann Surg. 2001 Jun;233(6):769-77 [11371735.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):244-9 [11393185.001]
  • [Cites] J Vasc Interv Radiol. 2001 Nov;12(11):1313-7 [11698631.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):853-9 [12115488.001]
  • [Cites] Am J Surg. 2002 Oct;184(4):353-5 [12383901.001]
  • [Cites] J Ultrasound Med. 2002 Nov;21(11):1221-6 [12418763.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):52-6 [12504658.001]
  • [Cites] Radiology. 2003 Mar;226(3):779-82 [12601206.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1824-31 [12673707.001]
  • [Cites] Acta Radiol. 2003 Jul;44(4):387-91 [12846688.001]
  • [Cites] Surgery. 2003 Oct;134(4):523-6; discussion 526-8 [14605609.001]
  • [Cites] Breast J. 2003 Nov-Dec;9(6):491-3 [14616944.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):357-64 [14681944.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):245-51 [14716757.001]
  • [Cites] Acad Radiol. 2004 Mar;11(3):293-308 [15035520.001]
  • [Cites] Cancer. 1986 Jan 15;57(2):320-3 [3942963.001]
  • [Cites] Surg Gynecol Obstet. 1990 May;170(5):407-10 [2183373.001]
  • [Cites] Eur J Surg Oncol. 1991 Jun;17(3):237-9 [2044776.001]
  • [Cites] Br J Surg. 1992 Oct;79(10):1042-5 [1422715.001]
  • [Cites] Radiology. 1993 May;187(2):507-11 [8475299.001]
  • [Cites] Radiology. 1994 Sep;192(3):793-5 [8058949.001]
  • [Cites] Radiology. 1994 Nov;193(2):325-6; discussion 326-8 [7972737.001]
  • [Cites] Radiology. 1994 Nov;193(2):359-64 [7972743.001]
  • [Cites] AJR Am J Roentgenol. 1996 Feb;166(2):341-6 [8553943.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):773-7 [8756371.001]
  • [Cites] Clin Radiol. 1996 Aug;51(8):562-5 [8761393.001]
  • [Cites] Cancer Detect Prev. 1996;20(6):620-4 [8939348.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2340-5 [8941004.001]
  • [Cites] Radiology. 1997 Apr;203(1):151-7 [9122384.001]
  • [Cites] AJR Am J Roentgenol. 1997 Sep;169(3):697-701 [9275881.001]
  • [Cites] J Am Coll Surg. 2000 Mar;190(3):299-303 [10703854.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1017-21 [10737383.001]
  • [Cites] Radiology. 2000 Jul;216(1):255-9 [10887257.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):542-8 [10998652.001]
  • [Cites] Clin Radiol. 1997 Oct;52(10):764-7 [9366536.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):932-9 [9637557.001]
  • [Cites] Radiology. 1998 Sep;208(3):717-23 [9722851.001]
  • [Cites] J Ultrasound Med. 2001 Jan;20(1):43-9 [11149527.001]
  • (PMID = 16244544.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1409862
  •  go-up   go-down


38. Ku J, Campbell C, Bennett I: Leiomyoma of the nipple. Breast J; 2006 Jul-Aug;12(4):377-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leiomyoma is a rare, benign neoplasm of the nipple.
  • Clinicians should be aware that this is a rare, but potential cause of chronic persistent pain and swelling in the region of the nipple-areola complex of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Leiomyoma / pathology. Nipples

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848853.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Yang J, Hu A, Wang L, Li B, Chen Y, Zhao W, Xu W, Li T: NOEY2 mutations in primary breast cancers and breast hyperplasia. Breast; 2009 Jun;18(3):197-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOEY2 mutations in primary breast cancers and breast hyperplasia.
  • PURPOSE: The NOEY2 gene mutations and protein expression in human breast cancers, adjacent breast tissues and breast benign lesions were analysed to explore the potential correlation between the mutation spectrum and breast cancer development and progression.
  • EXPERIMENTAL DESIGN: The promoter, exon and intron regions of NOEY2 gene were amplified by polymerase chain reaction (PCR) with DNA extracted from 50 human breast cancer and corresponding adjacent breast tissues as well as 50 breast benign lesions, respectively.
  • RESULTS: Twenty-one of 50 (42%) breast cancer mutations were identified in promoter (11 cases) and exon 2 (seven cases on untranslation region and three on coding region) and 17 of 50 (34%) adjacent breast tissues (all were atypical hyperplasia lesions) occurred mutations, including six promoter mutations and 11 exon 2 changes (10 cases on untranslation region and one on coding region).
  • Interestingly, the mutations were identified in both breast cancers and the corresponding adjacent breast tissues collected from the same patient in seven of them.
  • No mutation was identified in all benign breast tissues.
  • Immunohistochemical analysis showed that two of 17 mutational adjacent breast tissue samples were NOEY2 immunoreaction negative, and in all 21 mutations of breast cancers five cases were of loss of NOEY2 expression.
  • NOEY2 gene mutations were not correlated with patient ages, histological types, tumour sizes, histological grades, clinical stages, axillary lymph node metastases or with the condition of hormone receptor (ER, PR) expression and HER2 amplification.
  • CONCLUSIONS: The mutations of human NOEY2 were identified in human breast cancers and the corresponding adjacent breast tissues.
  • The presence of NOEY2 mutations in human breast cancer and early-stage lesions indicates that NOEY2 mutations may be partly associated with breast tumourigenesis.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. rho GTP-Binding Proteins / metabolism
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis / methods. Female. Gene Expression Regulation, Neoplastic. Humans. Hyperplasia / genetics. Hyperplasia / pathology. Immunohistochemistry. Middle Aged. Mutation. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19482475.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DIRAS3 protein, human; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


40. Tafuri LS, Rocha GF, Gobbi H: Cell cycle related proteins in hyperplasia of usual type in breast specimens of patients with and without breast cancer. BMC Cell Biol; 2006;7:29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle related proteins in hyperplasia of usual type in breast specimens of patients with and without breast cancer.
  • BACKGROUND: Hyperplasia of usual type (HUT) is a common proliferative lesion associated with a slight elevated risk for subsequent development of breast cancer.
  • The aim of this study was to analyze the expression of cell cycle related proteins in HUT of breast specimens of patients with and without breast cancer, and compare this expression with areas of invasive carcinomas.
  • RESULTS: Immunohistochemical evaluation was performed using antibodies against cell cycle related proteins ER, PR, p53, p21, p63, and Ki-67 in hyperplasia of usual type (HUT) in specimens of aesthetic reduction mammaplasty (ARM), in specimens of mammaplasty contralateral to breast cancer (MCC), and in specimens of invasive mammary carcinomas (IMC) presenting HUT in the adjacent parenchyma.
  • We also found cytoplasmic expression of p21 in benign hyperplastic lesions and in neoplastic cells of IMC.
  • CONCLUSION: Our data failed to demonstrate different expression of cell cycle related proteins in HUT from patients with and without breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Cycle Proteins / physiology. Hyperplasia / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Ki-67 Antigen / metabolism. Membrane Proteins / metabolism. Menopause / physiology. Middle Aged. Neoplasm Invasiveness / pathology. Proto-Oncogene Proteins p21(ras) / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1992 Feb 19;267(7):941-4 [1734106.001]
  • [Cites] Histopathology. 2005 Nov;47(5):458-66 [16241993.001]
  • [Cites] Br J Cancer. 1993 Sep;68(3):540-8 [8102535.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5545-9 [7777546.001]
  • [Cites] J Clin Pathol. 1995 Jul;48(7):611-5 [7560165.001]
  • [Cites] Eur J Cancer. 1995 Nov;31A(12):2049-52 [8562164.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):208-15 [8688323.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):297-301 [9149887.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1811-5 [10595909.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):966-78 [10888772.001]
  • [Cites] Pathol Res Pract. 2000;196(7):489-501 [10926327.001]
  • [Cites] Breast Cancer Res Treat. 2000 May;61(1):33-43 [10930088.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):104-10 [11082280.001]
  • [Cites] J Pathol. 2001 Mar;193(3):333-8 [11241412.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] J Clin Pathol. 2001 Nov;54(11):866-70 [11684722.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):185-97 [11981114.001]
  • [Cites] Breast Cancer. 2002;9(3):216-9 [12185332.001]
  • [Cites] Adv Anat Pathol. 2002 Sep;9(5):280-9 [12195217.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):214-20 [12610102.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):836-41 [12766590.001]
  • [Cites] Breast Cancer Res. 2003;5(6):R242-9 [14580260.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1143-50 [15492807.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):518-29 [2297643.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):37-42 [9428781.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] J Pathol. 1998 Mar;184(3):265-71 [9614378.001]
  • [Cites] Int J Cancer. 1998 Jun 10;76(6):891-6 [9626358.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1591-9 [9816338.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1539-45 [9865845.001]
  • [Cites] EMBO J. 1999 Mar 1;18(5):1223-34 [10064589.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):857-9 [15499614.001]
  • [Cites] J Pathol. 2005 Jan;205(2):248-54 [15641021.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):229-37 [16034008.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6949-52 [1458485.001]
  • (PMID = 16869981.001).
  • [ISSN] 1471-2121
  • [Journal-full-title] BMC cell biology
  • [ISO-abbreviation] BMC Cell Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC1563460
  •  go-up   go-down


41. Lee JH, Kim SH, Kang BJ, Lee AW, Song BJ: Ultrasonographic features of benign adenomyoepithelioma of the breast. Korean J Radiol; 2010 Sep-Oct;11(5):522-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonographic features of benign adenomyoepithelioma of the breast.
  • OBJECTIVE: The purpose of this study was to evaluate the ultrasonographic features of benign adenomyoepithelioma of the breast.
  • MATERIALS AND METHODS: Between 2005 and 2009, five patients had histologically confirmed adenomyoepithelioma of the breast.
  • We retrospectively evaluated the ultrasonographic findings of the tumors in correlation with the pathology, and reviewed medical records.
  • The ultrasonographic assessments were classified as Breast Imaging Reporting and Data System (BI-RADS) category 4A, with low suspicion of malignancy in two cases, and as category 4B, with intermediate suspicion of malignancy in three cases.
  • The pathology revealed benign adenomyoepithelioma in all patients.
  • CONCLUSION: Benign adenomyoepitheliomas appear as solid or complex echoic masses with suspicious malignant ultrasonographic features, which may be associated with adjacent ductectasia.
  • Although adenomyoepithelioma is a rare breast tumor, awareness of its sonographic features will be helpful for the differential diagnosis from other tumors.
  • [MeSH-major] Adenomyoepithelioma / ultrasonography. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Mammography. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):632-6 [10747327.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):488-90 [10834021.001]
  • [Cites] J Ultrasound Med. 2001 Sep;20(9):1021-4 [11549151.001]
  • [Cites] Breast J. 2002 Nov-Dec;8(6):383-4 [12390363.001]
  • [Cites] AJR Am J Roentgenol. 2003 Mar;180(3):799-803 [12591699.001]
  • [Cites] Breast. 2004 Aug;13(4):356-8 [15325675.001]
  • [Cites] Breast Cancer. 2007;14(4):429-33 [17986811.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1232-7 [2824328.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):554-68 [1709559.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):868-76 [1384377.001]
  • [Cites] Breast J. 2006 Jul-Aug;12(4):386 [16848857.001]
  • [Cites] Breast J. 2007 Mar-Apr;13(2):203-4 [17319866.001]
  • [Cites] Acta Radiol. 2007 Feb;48(1):27-9 [17325921.001]
  • [Cites] Curr Top Pathol. 1970;53:161-220 [4323195.001]
  • (PMID = 20808695.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2930160
  • [Keywords] NOTNLM ; Adenomyoepithelioma / Breast / Ultrasonography
  •  go-up   go-down


42. Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y, Imajo M, Kawaguchi M, Toi M, Mori T, Kawakita M: N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clin Cancer Res; 2005 Apr 15;11(8):2986-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
  • PURPOSE: N(1),N(12)-diacetylspermine (DiAcSpm) in the urine of colorectal and breast cancer patients was examined to establish its usefulness as a novel diagnostic tool for detecting these cancers at clinically early stages.
  • EXPERIMENTAL DESIGN: Urine samples from 248 colon cancer patients and 83 breast cancer patients as well as 51 patients with benign gastrointestinal diseases treated in Tokyo Metropolitan Komagome Hospital during the period of August 1999 to January 2004 were collected.
  • DiAcSpm was elevated in 60% of tumor-node-metastasis cancer stage 0 + I patients, whereas only 10% (P < 0.0001) and 5% (P < 0.0001) of these patients were CEA- and CA19-9-positive, respectively.
  • The sensitivity of urinary DiAcSpm for 83 cases of breast cancer (60.2%) was higher than the sensitivities of CEA (37.3%, P = 0.0032) and CA15-3 (37.3%, P = 0.0032).
  • DiAcSpm was elevated in 28% of tumor-node-metastasis stage I + II patients, whereas only 3% (P = 0.0064) and 0% (P = 0.001) of these patients were CEA- and CA15-3-positive, respectively.
  • CONCLUSION: The observations indicate that urinary DiAcSpm is a more sensitive marker than CEA, CA19-9, and CA15-3 and that it can efficiently detect colorectal and breast cancers at early stages.
  • [MeSH-major] Biomarkers, Tumor. Breast Neoplasms / diagnosis. Colorectal Neoplasms / diagnosis. Spermine / analogs & derivatives
  • [MeSH-minor] Adult. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Mucin-1 / blood. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837752.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Mucin-1; 2FZ7Y3VOQX / Spermine; 77928-71-3 / N',N''-diacetylspermine
  •  go-up   go-down


43. Münz M, Zeidler R, Gires O: The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett; 2005 Jul 8;225(1):151-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP.
  • The epithelial cell adhesion molecule, EpCAM, is a transmembrane glycoprotein associated with both benign and malignant proliferation.
  • In cancer cells, expression levels of this tumour-associated antigen correlate positively with the grade of dysplasia and are also a negative prognostic factor for breast cancer patients.
  • De novo expression of EpCAM resulted in the rapid upregulation of the proto-oncogene c-Myc along with enhanced cell proliferation and metabolism.
  • Taken together, these results provide further evidence for the direct involvement of EpCAM in signalling processes, gene regulation, and cellular metabolism supporting its important role in tumour biology.
  • [MeSH-major] Antigens, Neoplasm / physiology. Carcinoma, Squamous Cell / genetics. Cell Adhesion Molecules / physiology. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Antigens, Differentiation. Carrier Proteins. Cell Proliferation. Epithelial Cells. Fatty Acid-Binding Proteins. Fatty Acids. Genes, myc. Humans. Proteome. Signal Transduction. Tumor Cells, Cultured. Up-Regulation

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922867.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Antigens, Neoplasm; 0 / Carrier Proteins; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / FABP5 protein, human; 0 / Fatty Acid-Binding Proteins; 0 / Fatty Acids; 0 / Proteome
  •  go-up   go-down


44. Giri D: Recurrent challenges in the evaluation of fibroepithelial lesions. Arch Pathol Lab Med; 2009 May;133(5):713-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The morphologic spectrum of mammary fibroepithelial lesions ranges from fibroadenoma, a common benign neoplasm, to phyllodes tumor, an uncommon lesion that can sometimes recur and metastasize.
  • OBJECTIVE: To focus on problems encountered in the diagnostic evaluation of fibroepithelial tumors, highlighting the diagnostically relevant morphologic features and providing an update on the immunohistochemical profile and genetic alterations of these rare neoplasms.
  • DATA SOURCES: A PubMed search of the English-language literature identified published reports on fibroepithelial lesions, with a special focus on phyllodes tumor.
  • CONCLUSIONS: The distinction between fibroadenoma and phyllodes tumor is usually not problematic, especially in excision specimens.
  • Morphologic predictors of local recurrence of phyllodes tumor include cellularity and cytologic atypia, mitotic activity, positive margins, infiltrative borders, fibroproliferative satellite nodules, and past history of fibroadenoma.
  • Predictors of distant metastasis include size, tumor necrosis, and stromal overgrowth.
  • Presently, molecular and immunohistochemical techniques play a limited role in the diagnosis of fibroepithelial lesions.
  • [MeSH-major] Breast Neoplasms / diagnosis. Fibroadenoma / diagnosis. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Gene Expression. Humans. Immunoenzyme Techniques. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415945.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 46
  •  go-up   go-down


45. André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S: Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol; 2009 Apr;10(4):381-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.
  • BACKGROUND: Gene-expression arrays have generated molecular predictors of relapse and drug sensitivity in breast cancer.
  • We aimed to identify exons differently expressed in malignant and benign breast lesions and to generate a molecular classifier for breast-cancer diagnosis.
  • METHODS: 165 breast samples were obtained by fine-needle aspiration.
  • A nearest centroid prediction rule was developed to classify lesions as malignant or benign on a training set, and its performance was assessed on an independent validation set.
  • A two-way ANOVA model identified probe sets with differential expression in malignant and benign lesions while adjusting for scan dates.
  • FINDINGS: 120 breast cancers and 45 benign lesions were included in the study.
  • A molecular classifier for breast-cancer diagnosis with 1228 probe sets was generated from the training set (n=94).
  • In the validation set (n=71), the molecular predictor accurately classified 68 of 71 tumours (96%, 88-99%).
  • When the 165 samples were taken into account, 37 858 exon probe sets (5.4%) and 3733 genes (7.0%) were differently expressed in malignant and benign lesions (threshold: adjusted p<0.05).
  • In the same population of 165 samples, 956 exon probe sets presented both higher intensity and higher splice index in breast cancer than in benign lesions, although located on unchanged genes.
  • INTERPRETATION: Many exons are differently expressed by breast cancer and benign lesions, and alternative transcripts contribute to the molecular characteristics of breast malignancy.
  • Development of molecular classifiers for breast-cancer diagnosis with fine-needle aspiration should be possible.
  • [MeSH-major] Breast Neoplasms / genetics. Exons / genetics. Gene Expression Profiling. Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA Splicing / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Validation Studies as Topic. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Apr;10(4):314-5 [19341968.001]
  • (PMID = 19249242.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


46. Benarroch-Gampel J, Riall TS: Extrapancreatic malignancies and intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg; 2010 Oct 27;2(10):363-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrapancreatic malignancies and intraductal papillary mucinous neoplasms of the pancreas.
  • Over the last two decades multiple studies have demonstrated an increased incidence of additional malignancies in patients with intraductal papillary mucinous neoplasms (IPMNs).
  • The majority of these additional cancers occur before or concurrent with the diagnosis of IPMN.
  • The gastrointestinal tract is most commonly involved in secondary malignancies, with benign colon polyps and colon cancer commonly seen in western countries and gastric cancer commonly seen in Asian countries.
  • Other extrapancreatic malignancies associated with IPMNs include benign and malignant esophageal neoplasms, gastrointestinal stromal tumors, carcinoid tumors, hepatobiliary cancers, breast cancers, prostate cancers, and lung cancers.
  • Routine screening studies (breast and prostate) should be carried out as currently recommended for patient's age both before and after the diagnosis of IPMN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160845.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999205
  • [Keywords] NOTNLM ; Intraductal papillary mucinous neoplasm / Invasive / Malignant potential / Non-invasive / Secondary malignancy
  •  go-up   go-down


47. Sanz DJ, Acedo A, Infante M, Durán M, Pérez-Cabornero L, Esteban-Cardeñosa E, Lastra E, Pagani F, Miner C, Velasco EA: A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res; 2010 Mar 15;16(6):1957-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
  • We have investigated the effect of aberrant splicing of BRCA1/2 on hereditary breast/ovarian cancer (HBOC).
  • Splicing assays of 57 genetic variants were done by lymphocyte reverse transcription-PCR and/or hybrid minigenes in HeLa and nontumor breast epithelial cells.
  • To further evaluate the defective splicing of BRCA1/2, we analyzed 31 Breast Cancer Information Core Database (BIC) and two artificial variants that were generated by mutagenesis.
  • The identification of splicing disruptions by functional assays is a valuable tool to discriminate between benign polymorphisms and pathogenic mutations.
  • [MeSH-major] Alternative Splicing. BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / genetics. Genetic Variation / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Age of Onset. DNA Primers / chemistry. DNA, Neoplasm / genetics. Female. Genetic Predisposition to Disease. Humans. Lymphocytes. Mutagenesis, Site-Directed. Mutation / genetics. Phenotype. Polymerase Chain Reaction. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics


48. Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM: Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology; 2008 Jul;248(1):79-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
  • PURPOSE: To retrospectively evaluate high-spatial-resolution signal enhancement ratio (SER) imaging for the prediction of disease recurrence in patients with breast cancer who underwent preoperative magnetic resonance (MR) imaging.
  • From 1995 to 2002, gadolinium-enhanced MR imaging data were acquired with a three time point high-resolution method in women undergoing neoadjuvant therapy for invasive breast cancers.
  • RESULTS: Breast tumor volume calculated from the number of voxels with SER values above a threshold corresponding to the upper limit of mean redistribution rate constant in benign tumors (0.88 minutes(-1)) and the volume of cancerous breast tissue infiltrating into the parenchyma were important predictors of disease recurrence.
  • All three prechemotherapy parameters (total tumor volume, tumor volumes with high and low SER) and the postchemotherapy tumor volume with high SER were significantly different between the two groups.
  • The multivariate Cox proportional hazards regression showed that, of the three prechemotherapy covariates, only the low SER and high SER tumor volumes (P = .017 and .049, respectively) were significant and independent predictors of tumor recurrence.
  • Tumor volume with high SER was the only significant postchemotherapy covariate predictor (P = .038).
  • [MeSH-major] Breast Neoplasms / diagnosis. Image Enhancement / methods. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • [Cites] Med Phys. 1987 Jan-Feb;14(1):1-37 [3031439.001]
  • [Cites] J Magn Reson Imaging. 1997 Jan-Feb;7(1):91-101 [9039598.001]
  • [Cites] Radiology. 2005 Sep;236(3):789-800 [16118161.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):260-6 [10508285.001]
  • [Cites] Radiology. 1999 Apr;211(1):101-10 [10189459.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jun;184(6):1774-81 [15908529.001]
  • [Cites] Breast J. 1999 Jan;5(1):13-21 [11348250.001]
  • [Cites] Crit Rev Diagn Imaging. 1995;36(4):287-338 [8845065.001]
  • [Cites] Clin Radiol. 1997 Jul;52(7):516-26 [9240704.001]
  • [Cites] J Magn Reson Imaging. 2003 Oct;18(4):467-77 [14508784.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2001 May;9(2):321-32, vi [11493422.001]
  • [Cites] Magn Reson Med. 1995 Apr;33(4):564-8 [7776889.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Acta Radiol. 2003 Jul;44(4):373-8 [12846686.001]
  • [Cites] Radiology. 2006 May;239(2):361-74 [16543585.001]
  • [Cites] Cancer. 1996 May 1;77(9):1844-9 [8646683.001]
  • [Cites] Br J Radiol. 1998 May;71(845):501-9 [9691895.001]
  • [Cites] Breast Cancer Res Treat. 1997 Aug;45(1):39-46 [9285115.001]
  • [Cites] Magn Reson Med. 2007 Sep;58(3):572-81 [17685424.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):965-74 [11105038.001]
  • [Cites] Radiology. 1995 Oct;197(1):33-8 [7568850.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):708-18 [15971199.001]
  • [Cites] Acta Radiol. 1998 May;39(3):279-84 [9571944.001]
  • [Cites] Eur J Radiol. 2005 Feb;53(2):199-205 [15664283.001]
  • [Cites] Radiology. 1997 Dec;205(3):837-42 [9393545.001]
  • [Cites] J Magn Reson Imaging. 1999 Dec;10(6):945-9 [10581507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):910-2 [11183740.001]
  • [Cites] J Comput Assist Tomogr. 2002 May-Jun;26(3):376-86 [12016367.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23(4):615-21 [10433296.001]
  • [Cites] Br J Radiol. 1997 May;70(833):446-51 [9227224.001]
  • [Cites] Eur Radiol. 2001;11(9):1645-50 [11511885.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):97-103 [8630946.001]
  • [Cites] J Magn Reson Imaging. 2005 Oct;22(4):511-9 [16161072.001]
  • [Cites] Magn Reson Imaging. 2004 May;22(4):475-81 [15120166.001]
  • (PMID = 18566170.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069587; United States / NCI NIH HHS / CA / R01 CA116182
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Balasenthil S, Broaddus RR, Kumar R: Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum Pathol; 2006 Jun;37(6):656-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas.
  • Metastasis-associated protein 1 (MTA1) is a component of the Mi-2/nucleosome remodeling and deacetylating complex and acts as a potent corepressor of estrogen receptor in breast cancer cells.
  • We investigated the expression profile of MTA1 in different stages of benign endometrium as well as in endometrial endometrioid adenocarcinoma using immunohistochemistry and Western blotting.
  • Western blot analysis of 6 tumor specimens showed increased expression of MTA1 in all the tumors analyzed.
  • Immunohistochemical staining performed on tumor microarray containing 70 endometrial endometrioid adenocarcinomas of various grades showed increased expression of MTA1 in 53 (75.7%) tumors.
  • In grade 1 and grade 2 tumors, MTA1 was present in both nucleus and cytoplasm.
  • Interestingly, in grade 3 tumors, MTA1 was localized in the cytoplasm only.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Endometrium / metabolism. Gene Expression. Histone Deacetylases / metabolism. Repressor Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry. Neoplasm Staging

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733204.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 098823
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


50. Goicoechea SM, Bednarski B, García-Mata R, Prentice-Dunn H, Kim HJ, Otey CA: Palladin contributes to invasive motility in human breast cancer cells. Oncogene; 2009 Jan 29;28(4):587-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palladin contributes to invasive motility in human breast cancer cells.
  • In this study, we found that the protein palladin, a molecular scaffold with an important function in actin organization, is expressed at higher overall levels in tumors compared with benign breast tissue, and also expressed significantly higher in four invasive breast cancer cell lines when compared with four non-invasive cell lines.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 2006;38(11):1875-92 [16790362.001]
  • [Cites] Exp Cell Res. 2006 Apr 15;312(7):974-82 [16430883.001]
  • [Cites] Proteomics. 2006 Aug;6(15):4402-9 [16807943.001]
  • [Cites] J Cell Physiol. 2006 Nov;209(2):568-79 [16897755.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2387-96 [16794588.001]
  • [Cites] Proteomics. 2006 Dec;6(23):6300-16 [17133371.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e516 [17194196.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):296-305 [17211471.001]
  • [Cites] Breast Cancer Res Treat. 1999 Dec;58(3):193-204 [10718481.001]
  • [Cites] J Cell Biol. 2000 Aug 7;150(3):643-56 [10931874.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1833-8 [11280733.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5168-78 [11431356.001]
  • [Cites] Mol Biol Cell. 2001 Sep;12(9):2721-9 [11553711.001]
  • [Cites] Mol Biol Cell. 2001 Oct;12(10):3060-73 [11598191.001]
  • [Cites] Exp Cell Res. 2002 Oct 15;280(1):64-74 [12372340.001]
  • [Cites] Mol Biol Cell. 2003 Jun;14(6):2482-91 [12808045.001]
  • [Cites] Trends Cell Biol. 2003 Jul;13(7):376-85 [12837608.001]
  • [Cites] Trends Cell Biol. 2007 Mar;17(3):107-17 [17275303.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2657-65 [17363586.001]
  • [Cites] J Cell Biochem. 2007 Apr 1;100(5):1288-300 [17115415.001]
  • [Cites] Circ Res. 2007 Mar 30;100(6):817-25 [17322171.001]
  • [Cites] Biochim Biophys Acta. 2007 May;1773(5):642-52 [16926057.001]
  • [Cites] Immunity. 2007 Jun;26(6):784-97 [17570692.001]
  • [Cites] Exp Cell Res. 2007 Jul 15;313(12):2575-85 [17537434.001]
  • [Cites] Cancer Lett. 2007 Oct 8;255(2):205-18 [17537571.001]
  • [Cites] J Clin Invest. 2007 Oct;117(10):2962-73 [17885682.001]
  • [Cites] BMC Cancer. 2007;7:198 [17956604.001]
  • [Cites] J Biol Chem. 2008 Mar 7;283(10):6222-31 [18180288.001]
  • [Cites] Mol Cell Neurosci. 2003 Aug;23(4):661-8 [12932445.001]
  • [Cites] Cell Motil Cytoskeleton. 2004 Feb;57(2):84-95 [14691948.001]
  • [Cites] Cell Motil Cytoskeleton. 2004 May;58(1):17-29 [14983521.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1600-8 [14767055.001]
  • [Cites] J Cell Biol. 2004 May 10;165(3):421-32 [15138294.001]
  • [Cites] FEBS Lett. 2004 May 21;566(1-3):30-4 [15147863.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Aug;5(8):647-57 [15366708.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5702-10 [7923219.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1383-93 [9508771.001]
  • [Cites] Clin Exp Metastasis. 1998 Aug;16(6):501-12 [9872598.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4440-9 [10442635.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):155-65 [15710328.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):138-45 [15752977.001]
  • [Cites] J Cell Mol Med. 2005 Jan-Mar;9(1):208-21 [15784178.001]
  • [Cites] Mol Cell Neurosci. 2005 Aug;29(4):507-15 [15950489.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6130-8 [16024614.001]
  • [Cites] Int Rev Cytol. 2005;246:31-58 [16164966.001]
  • [Cites] Exp Cell Res. 2005 Oct 15;310(1):88-98 [16125169.001]
  • [Cites] FEBS J. 2006 Jan;273(1):26-33 [16367745.001]
  • [Cites] J Cell Sci. 2006 Mar 15;119(Pt 6):995-1004 [16492705.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):151-7 [16546557.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):213-8 [16546563.001]
  • [Cites] J Cell Sci. 2006 Aug 15;119(Pt 16):3316-24 [16868024.001]
  • (PMID = 18978809.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009688; United States / NIGMS NIH HHS / GM / GM61743; United States / NIGMS NIH HHS / GM / R01 GM061743; United States / NIGMS NIH HHS / GM / GM061743-04; United States / NIGMS NIH HHS / GM / R01 GM061743-04; United States / NCI NIH HHS / CA / CA098240; United States / NCI NIH HHS / CA / CA09688; United States / NCI NIH HHS / CA / K08 CA098240
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Cytoskeletal Proteins; 0 / Phosphoproteins; 0 / palladin protein, human; 0 / palladin protein, mouse
  • [Other-IDs] NLM/ NIHMS72118; NLM/ PMC2633435
  •  go-up   go-down


51. Arpino G, Laucirica R, Elledge RM: Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med; 2005 Sep 20;143(6):446-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premalignant and in situ breast disease: biology and clinical implications.
  • Most types of invasive breast cancer are thought to evolve over long periods from specific preexisting benign lesions.
  • Of the many types of benign entities found in the human breast, only a few have clinically significant premalignant potential.
  • The development of modern molecular genetic techniques has allowed breast cancer researchers to clarify the multistep model of breast carcinogenesis.
  • Options for breast cancer risk reduction and prevention are available.
  • [MeSH-major] Breast / pathology. Carcinoma in Situ / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Disease Progression. Female. Humans. Hyperplasia / pathology. Neoplasm Invasiveness. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172443.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA30195; United States / NCI NIH HHS / CA / P50 CA58183; United States / NCI NIH HHS / CA / U-19 CA86809
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


52. Choi N, Ko ES: Invasive ductal carcinoma in a mammary hamartoma: case report and review of the literature. Korean J Radiol; 2010 Nov-Dec;11(6):687-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammary hamartomas are typically a benign condition and rarely develop into malignant lesions.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Hamartoma / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Mammography. Mastectomy, Modified Radical. Neoplasm Invasiveness. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):64-6 [10882247.001]
  • [Cites] Indian J Pathol Microbiol. 2009 Apr-Jun;52(2):249-51 [19332930.001]
  • [Cites] J Clin Pathol. 2002 Jul;55(7):541-2 [12101205.001]
  • [Cites] Clin Radiol. 2003 Jan;58(1):80-3 [12565210.001]
  • [Cites] Breast J. 2003 May-Jun;9(3):246-8 [12752637.001]
  • [Cites] Yonsei Med J. 2003 Oct 30;44(5):847-54 [14584102.001]
  • [Cites] Surg Gynecol Obstet. 1971 Oct;133(4):577-82 [5096305.001]
  • [Cites] Acta Radiol Diagn (Stockh). 1982;23(5):503-5 [7158415.001]
  • [Cites] Radiology. 1989 Feb;170(2):417-21 [2911664.001]
  • [Cites] J Clin Pathol. 1992 Oct;45(10):936-7 [1430271.001]
  • [Cites] Am J Clin Pathol. 1995 Jun;103(6):685-9 [7785651.001]
  • [Cites] Pathol Res Pract. 1996 Dec;192(12):1187-94 [9182287.001]
  • [Cites] Breast J. 2006 Jul-Aug;12(4):368-70 [16848850.001]
  • [Cites] J Ultrasound Med. 2007 Apr;26(4):447-52; quiz 453 [17384041.001]
  • [Cites] J Clin Pathol. 2002 Jan;55(1):76-7 [11825932.001]
  • (PMID = 21076596.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2974232
  • [Keywords] NOTNLM ; Invasive ductal carcinoma / Mammary hamartoma
  •  go-up   go-down


53. Nese N, Kandiloglu AR, Simsek G, Lekili M, Ozdamar A, Catalkaya A, Coskun T: Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin. Anal Quant Cytol Histol; 2010 Apr;32(2):90-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin.
  • RESULTS: HSP47 and fascin were localized to cytoplasm, and HSP47 and fascin IR were higher in IDC and PCa than benign groups (p < 0.05).
  • Fascin expression correlated with estrogen receptor and progesterone receptor negativity, tumor size and stage in IDC and surgical margin status in PCa.
  • Although there is no relationship with recurrence or metastatic status, fascin overexpression correlated with tumor size, which may prompt its use as a prognostic factor in IDC.


54. Engers R, Mueller M, Walter A, Collard JG, Willers R, Gabbert HE: Prognostic relevance of Tiam1 protein expression in prostate carcinomas. Br J Cancer; 2006 Oct 23;95(8):1081-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Rac-specific guanine nucleotide exchange factor, Tiam1, plays a major role in oncogenicity, tumour invasion and metastasis but its usefulness as a prognostic marker in human cancer has not been tested yet.
  • In the present study, Tiam1 expression was analysed in benign secretory epithelium, pre-neoplastic high-grade prostatic intraepithelium neoplasia (HG-PIN) and prostate carcinomas of 60 R0-resected radical prostatectomy specimens by semiquantitative immunohistochemistry.
  • Tiam1 proved significantly overexpressed in both HG-PIN (P<0.001) and prostate carcinomas (P<0.001) when compared to benign secretory epithelium.
  • > or =3.5-fold) in prostate carcinomas relative to the respective benign prostatic epithelium was statistically significantly associated with disease recurrence (P=0.016), the presence of lymph vessel invasion (P=0.031) and high Gleason scores (GS) (i.e.
  • Together, our data suggest that strong Tiam1 overexpression relative to the corresponding benign epithelial cells is a new and independent predictor of decreased DFS for patients with prostate cancer.
  • [MeSH-major] Guanine Nucleotide Exchange Factors / biosynthesis. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28443-50 [11328805.001]
  • [Cites] Eur J Clin Invest. 2002 Jun;32(6):448-57 [12059991.001]
  • [Cites] Nature. 2002 Jun 20;417(6891):867-71 [12075356.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):21-32 [14999151.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):239-43 [15043314.001]
  • [Cites] Am J Clin Pathol. 2003 Dec;120 Suppl:S85-100 [15298146.001]
  • [Cites] NCI Monogr. 1988;(7):15-8 [3173500.001]
  • [Cites] Cell. 1994 May 20;77(4):537-49 [7999144.001]
  • [Cites] Gynecol Oncol. 1994 May;53(2):220-7 [8188083.001]
  • [Cites] Nature. 1995 Mar 30;374(6521):457-9 [7700355.001]
  • [Cites] Nature. 1995 May 25;375(6529):338-40 [7753201.001]
  • [Cites] Cell. 1995 Jun 30;81(7):1137-46 [7600581.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):23934-6 [7592586.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2215-21 [8570171.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3707-13 [8668187.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):286-92 [8772781.001]
  • [Cites] Science. 1997 Nov 21;278(5342):1464-6 [9367959.001]
  • [Cites] Nature. 1997 Dec 11;390(6660):632-6 [9403696.001]
  • [Cites] J Cell Biol. 1998 Nov 30;143(5):1385-98 [9832565.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(2):119-26 [15809669.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):1-22 [16195239.001]
  • [Cites] J Biol Chem. 2006 Jan 6;281(1):543-8 [16249175.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):369-76 [11054665.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):167-73 [11322835.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):41889-97 [11551917.001]
  • (PMID = 17003780.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Guanine Nucleotide Exchange Factors; 0 / TIAM1 protein, human
  • [Other-IDs] NLM/ PMC2360703
  •  go-up   go-down


55. Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD: Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol; 2005 Apr;192(4):1230-7; discussion 1237-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
  • OBJECTIVE: This study was undertaken to report on the benign gynecologic conditions occurring among women with an intact uterus at enrollment in the Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project.
  • STUDY DESIGN: The incidence rates of several benign gynecologic conditions were determined and risks were compared among women receiving tamoxifen and those receiving placebo, based on risk ratios (RRs) with 95% CIs.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / therapy. Genital Diseases, Female / chemically induced. Genital Diseases, Female / pathology. Neoplasm Recurrence, Local / prevention & control. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Age Distribution. Aged. Chemotherapy, Adjuvant. Confidence Intervals. Dose-Response Relationship, Drug. Female. Humans. Incidence. Middle Aged. Neoplasm Staging. Probability. Reference Values. Risk Assessment

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2006 Apr;194(4):1204-5; author reply 1205 [16580343.001]
  • (PMID = 15846210.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


56. Gozzi G, Martinoli C, Conti GM, Ganzetti A, Bodini M, Fiorentino C, Marini UP, Santini D, Bacigalupo L: Screening mammography interpretation test: more frequent mistakes. Radiol Med; 2005 Mar;109(3):268-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mammograms had been taken in the four standard projections and placed on four multi-panel diaphanoscopes, each displaying a set of 40 cases comprising benign and malignant cases in equal proportions.
  • As regards the 23 most frequently misread cases, these were 10/32 (31.25%) mammograms positive for malignancy and 13/128 (10.15%) negative mammograms or mammograms showing benign disease.
  • The 13 cases of benign disease--as established by histology or long-term follow-up--mistaken for malignancies by the test participants were fibrocystic breast disease in 5 cases, surgical scar in 1 case, ABBI scar in 1 case, radial scar in 2 cases, microcalcifications that had remained stable for years in 2 cases, focal sclero-adenosis in 1 case and sclero-elastosis in 1 case.
  • CONCLUSIONS: The errors were due to microcalcifications, benign disease simulating a neoplasm, overlapping tissue, visibility of a lesion in one projection only, lesion site in relation to the corpus mammae, missed areas of asymmetry.
  • Attention must be paid to these signs of focal breast disease since, if correctly evaluated, they enable the early diagnosis of low-grade carcinomas that frequently carry a favourable prognosis.
  • [MeSH-major] Breast Neoplasms / radiography. Diagnostic Errors. Mammography. Mass Screening. Radiology / standards
  • [MeSH-minor] Adenocarcinoma / radiography. Breast Diseases / surgery. Calcinosis / radiography. Carcinoma in Situ / radiography. Carcinoma, Ductal, Breast / radiography. Cicatrix / surgery. False Negative Reactions. False Positive Reactions. Female. Fibrocystic Breast Disease / radiography. Follow-Up Studies. Humans. Observer Variation


57. Szabo-Moskal J, Lasek W, Kozłowska R, Sir J, Serafin Z: [The role of preoperative hooked-wire localization of occult lesions for early detection of breast cancer]. Ginekol Pol; 2005 Jan;76(1):15-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of preoperative hooked-wire localization of occult lesions for early detection of breast cancer].
  • OBJECTIVES: Nonpalpable small lesions, usually few millimeters in diameter, consist an important problem in the early diagnostics of breast cancer.
  • DESIGN: An aim of this paper was an evaluation of usefulness of preoperative hooked-wire localization of such lesions for the detection of breast cancer.
  • RESULTS: Histologic examination of the localized lesions revealed benign changes in 71.2%, atypical ductal hyperplasia in 4.6% and cancer in 24.2%.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Mammography. Middle Aged. Neoplasm Invasiveness. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844561.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


58. Dhingra KK, Mandal S, Roy S, Khurana N: Malignant peripheral nerve sheath tumor of the breast: case report. World J Surg Oncol; 2007;5:142
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor of the breast: case report.
  • BACKGROUND: Malignant peripheral nerve sheath tumor is a rare soft tissue sarcoma of ectomesenchymal origin.
  • It is the malignant counterpart of benign soft tissue tumors like neurofibromas and schwannomas and may often follow them.
  • Breast is an extremely rare location of this lesion and presentation as a breast lump in the absence of pain or previous benign neural tumor is even rarer.
  • CASE PRESENTATION: A 38-year-old female presented with complaints of painless, hard breast lump for three months which was clinically suspected to be a ductal carcinoma with inconclusive fine needle aspiration cytology.
  • Histopathology revealed a malignant spindle cell tumor which was confirmed to be malignant peripheral nerve sheath tumor on the basis of immunopositivity for vimentin, neurone specific enolase and S-100.
  • The differential diagnosis of malignant peripheral nerve sheath tumor should be considered by the clinician as well as the pathologists in the work-up of a breast neoplasm as treatment and prognosis of this rare malignancy is different.
  • [MeSH-major] Breast Neoplasms / pathology. Nerve Sheath Neoplasms / pathology. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Vimentin / metabolism

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orv Hetil. 1998 Jan 18;139(3):137-9 [9467297.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1049-57 [6432304.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):155-60 [2447857.001]
  • [Cites] J Surg Oncol. 1995 Aug;59(4):273-5 [7630177.001]
  • [Cites] J Med Assoc Thai. 2006 Mar;89(3):377-9 [16696423.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Breast J. 2003 Jul-Aug;9(4):332 [12846874.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 1998 Jun;27(4):441-4 [9690165.001]
  • [Cites] Langenbecks Arch Chir. 1995;380(6):350-3 [8559005.001]
  • (PMID = 18154670.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vimentin
  • [Other-IDs] NLM/ PMC2246134
  •  go-up   go-down


59. Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P, Benign Breast Diseases Study Group: Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci U S A; 2008 Sep 23;105(38):14533-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
  • Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of Prl/PrlR genes may be related to the occurrence of breast diseases with high proliferative potential.
  • Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
  • Constitutive activity of PrlR(I146L) in the breast sample from a patient was supported by increased STAT5 signaling.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Fibroadenoma / genetics. Fibroadenoma / metabolism. Mutation, Missense. Receptors, Prolactin / genetics. Receptors, Prolactin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Guide to Pharmacology. gene/protein/disease-specific - Prolactin-releasing peptide receptor - overview and references .
  • Guide to Pharmacology. gene/protein/disease-specific - PrRP receptor - data and references .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):665-71 [14696092.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4056-66 [16809439.001]
  • [Cites] Curr Med Res Opin. 2004 Apr;20(4):533-40 [15119991.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2053-60 [15169792.001]
  • [Cites] Acta Obstet Gynecol Scand. 1987;66(6):483-8 [3321867.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4031-5 [7537382.001]
  • [Cites] Mol Endocrinol. 1996 Jan;10(1):45-56 [8838144.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29707-14 [8939904.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):667-74 [9467590.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35 [16900392.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):571-81 [17024156.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):989-1008 [17138649.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):841-4 [17299388.001]
  • [Cites] BMC Med Genet. 2007;8:72 [18053149.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4664-74 [12879011.001]
  • [Cites] Front Biosci. 2000 Mar 1;5:D343-52 [10704433.001]
  • [Cites] Nat Struct Biol. 2000 Sep;7(9):808-15 [10966654.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3826-32 [11502819.001]
  • [Cites] J Endocrinol. 2001 Oct;171(1):R1-4 [11572805.001]
  • [Cites] J Clin Pathol. 2001 Dec;54(12):956-60 [11729217.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):49-66 [12160086.001]
  • [Cites] Endocrine. 2003 Feb-Mar;20(1-2):177-90 [12668884.001]
  • [Cites] Recent Prog Horm Res. 2003;58:297-323 [12795425.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):35988-99 [12824168.001]
  • [Cites] Endocr Rev. 1998 Jun;19(3):225-68 [9626554.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10024-34 [10187780.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):629-34 [10203283.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):275-85 [16034013.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):555-62 [16278261.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1513-9 [16434456.001]
  • [Cites] J Endocrinol. 2006 Aug;190(2):271-85 [16899561.001]
  • [Cites] Biol Reprod. 2004 Mar;70(3):718-28 [14613905.001]
  • (PMID = 18779591.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Receptors, Prolactin; 0 / STAT5 Transcription Factor; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
  • [Other-IDs] NLM/ PMC2567233
  • [Investigator] Bachelot A; Belaroussi B; Bensimhon J; Berdah J; Blin MJ; Boudinet A; Brethon B; Bricaire C; Caby J; Caillaud G; Carel JC; Chabbert-Buffet N; Charitanski H; Chretien C; Clough K; Courtillot C; Delattre G; Denys I; Desthieux-Ngo K; Detoeuf M; Dhainault C; Duflos C; Fiori O; Genestie C; Gibaud G; Gompel A; Gracia C; Grimard A; Hofman C; Hofman H; Kuttenn F; Laki F; Lanty C; Lefranc JP; Le Frere-Belda MA; Leger D; Martinez F; May A; Meng L; Nos C; Pelletier D; Perrin A; Plu-Bureau G; Raccah-Tebbeca B; Saiovici JC; Salmon R; Sibout M; Sigal-Zafrani B; Thalabard JC; Thibaud E; Thoury A; Touraine P; Triana-Rabi KB; Uzan S; Viriot J; Yacoub S
  •  go-up   go-down


60. Zhong XY, Ladewig A, Schmid S, Wight E, Hahn S, Holzgreve W: Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet; 2007 Oct;276(4):327-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated level of cell-free plasma DNA is associated with breast cancer.
  • BACKGROUND: We analysed cell-free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions by real-time quantitative PCR to determine whether the finding may have diagnostic and prognostic implications.
  • METHODS: Plasma samples were obtained from 33 patients with breast cancer, 32 patients with benign breast lesions and 50 healthy women as normal controls.
  • RESULTS: The mean concentrations of cfDNA in the plasma samples from patients with breast cancer, patients with benign breast lesions and normal controls were 2,285, 1,368 and 1,489 genome equivalents (GE) per millilitre, respectively.
  • The level of cfDNA in the breast cancer group was significantly higher than those in the benign lesion group and control group (P = 0.007 and 0.013, respectively).
  • These findings were associated with malignant tumour size.
  • CONCLUSIONS: Our results suggest that levels of cfDNA in the plasma are elevated in malignant breast cancer and correlated with tumour size.
  • These findings could have diagnostic and prognostic value for malignant breast tumours.
  • [MeSH-major] Breast Neoplasms / blood. DNA / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Breast Diseases / blood. Cell-Free System. Cohort Studies. Female. Humans. Middle Aged. Neoplasm Staging. Plasma / chemistry. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431649.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-49-2 / DNA
  •  go-up   go-down


61. Javid SH, Carlson JW, Garber JE, Birdwell RL, Lester S, Lipsitz S, Golshan M: Breast MRI wire-guided excisional biopsy: specimen size as compared to mammogram wire-guided excisional biopsy and implications for use. Ann Surg Oncol; 2007 Dec;14(12):3352-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast MRI wire-guided excisional biopsy: specimen size as compared to mammogram wire-guided excisional biopsy and implications for use.
  • BACKGROUND: Breast magnetic resonance imaging (MRI) has been implemented as a screening tool for early detection and as a diagnostic test in the management of breast cancer.
  • We also sought to evaluate factors that might predict the presence of breast cancer in patients undergoing MRIbx.
  • METHODS: We reviewed consecutive cases of breast MRIbx from 2004 to 2006 performed by seven surgeons.
  • MRI was performed in patients with either a synchronous breast cancer or significant risk factors.
  • Eleven (15.5%) invasive breast cancers and eight cases (11.3%) of ductal carcinoma in situ (DCIS) were identified.
  • DCIS-containing MRIbx specimens were significantly larger than benign or invasive cancer-containing specimens.
  • CONCLUSIONS: In patients undergoing breast MRIbx, 27% were found to have DCIS or invasive breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / surgery. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Biopsy, Needle. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / surgery. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / surgery. Female. Humans. Mammography. Middle Aged. Neoplasm Invasiveness / pathology. Predictive Value of Tests. Prospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17849165.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S, Chinnaiyan AM: Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene; 2008 Dec 11;27(58):7274-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder.
  • The mechanism by which EZH2 mediates tumor aggressiveness is unclear.
  • Here, we demonstrate that EZH2 mediates transcriptional silencing of the tumor suppressor gene E-cadherin by trimethylation of H3 lysine 27.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1999 Dec;23(4):474-8 [10581039.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7274-9 [10602481.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):992-1005 [10931041.001]
  • [Cites] Nat Cell Biol. 2002 Mar;4(3):222-31 [11836526.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Biochim Biophys Acta. 2002 Jun 21;1602(2):151-61 [12020801.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]
  • [Cites] Science. 2003 Apr 4;300(5616):131-5 [12649488.001]
  • [Cites] J Natl Cancer Inst. 2003 May 7;95(9):661-8 [12734317.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):575-81 [12841864.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):306-19 [14673164.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1592-605 [15231737.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):78-84 [15272533.001]
  • [Cites] Br J Cancer. 1982 Mar;45(3):361-6 [7073932.001]
  • [Cites] Cell. 1983 Sep;34(2):455-66 [6352050.001]
  • [Cites] Surg Clin North Am. 1990 Aug;70(4):937-62 [2371651.001]
  • [Cites] J Cell Biol. 1991 Apr;113(1):173-85 [2007622.001]
  • [Cites] J Pathol. 1993 Feb;169(2):245-50 [8383197.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1690-5 [8453643.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1696-701 [8453644.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3618-23 [8339268.001]
  • [Cites] Am J Pathol. 1993 Dec;143(6):1731-42 [8256859.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3929-33 [7518346.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):614-6 [7880746.001]
  • [Cites] Oncogene. 1995 Oct 5;11(7):1319-26 [7478552.001]
  • [Cites] Virchows Arch. 1995;427(3):259-63 [7496594.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):374-7 [9291424.001]
  • [Cites] J Biol Chem. 1999 Apr 2;274(14):9656-64 [10092652.001]
  • [Cites] Semin Cell Dev Biol. 1999 Apr;10(2):227-35 [10441076.001]
  • [Cites] Biochim Biophys Acta. 1999 Oct 6;1447(1):1-16 [10500238.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8629-38 [15467754.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(1):389-402 [15601859.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):736-43 [15720799.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1754-8 [15856046.001]
  • [Cites] World J Gastroenterol. 2005 May 28;11(20):3139-43 [15918205.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22437-44 [15817459.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):349-53 [16012774.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):31470-7 [16009709.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):268-73 [16330673.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):794-5 [16482140.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Genes Dev. 2006 May 1;20(9):1123-36 [16618801.001]
  • [Cites] Nature. 2006 May 18;441(7091):349-53 [16625203.001]
  • [Cites] Nat Genet. 2006 Jun;38(6):694-9 [16628213.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):846-56 [17060944.001]
  • [Cites] Genes Dev. 2006 Dec 1;20(23):3199-214 [17158740.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Prostate. 2007 Apr 1;67(5):547-56 [17252556.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1050-63 [17437993.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4590-5 [17237810.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):419-31 [17996646.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10657-63 [18006806.001]
  • [Cites] Cancer Sci. 2008 Apr;99(4):738-46 [18377425.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):741-50 [18488029.001]
  • (PMID = 18806826.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129565-01A1; United States / NCI NIH HHS / CA / P50 CA069568-110020; United States / NCI NIH HHS / CA / K99 CA129565-01A1; United States / NCI NIH HHS / CA / CA111275-04; United States / NCI NIH HHS / CA / P50 CA69568; United States / NCI NIH HHS / CA / P50 CA069568-06A10016; United States / NCI NIH HHS / CA / CA069568-110020; United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / CA069568-06A10016; United States / NCI NIH HHS / CA / K99 CA129565; United States / NCI NIH HHS / CA / U01 CA111275-04; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / U01 CA111275; United States / NCI NIH HHS / CA / R01 CA097063; United States / NCI NIH HHS / CA / R01 CA97063
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / DNA-Binding Proteins; 0 / Histones; 0 / Polycomb-Group Proteins; 0 / Repressor Proteins; 0 / Transcription Factors; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2
  • [Other-IDs] NLM/ NIHMS104449; NLM/ PMC2690514
  •  go-up   go-down


63. Suga K, Kawakami Y, Hiyama A, Matsunaga N: Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan. Ann Nucl Med; 2009 Jun;23(4):399-407
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
  • OBJECTIVE: To evaluate the ability of dual-time point F-18-fluorodeoxy-glucose (FDG) PET/CT scans to differentiate FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer.
  • METHODS: A total of 64 FDG-avid recurrent lesions (local tumor recurrence or lymph node metastases) in 52 patients and 38 FDG-avid compromised benign lesions after surgery in 37 patients were included in the study.
  • RESULTS: The average early SUVmax, delayed SUVmax and DeltaSUVmax% were 4.9 +/- 2.6, 6.0 +/- 3.6 and 18.2% +/- 18.8 in FDG-avid recurrent lesions, and 2.1 +/- 0.8, 1.8 +/- 1.0 and -17.8% +/- 21.3 in FDG-avid benign lesions, respectively.
  • Delayed SUVmax was significantly increased compared with early SUVmax in recurrent lesions (P < 0.0001), while it was decreased in benign lesions (P < 0.0001).
  • All the three parameters in recurrent lesions were significantly higher than those in benign lesions (P < 0.0001).
  • CONCLUSIONS: This approach with SUVmax estimation appears to improve the differentiation between FDG-avid loco-regional recurrent of breast cancer and compromised benign lesions after surgery, since delayed scanning significantly enhances the difference in FDG uptake between these lesions.
  • [MeSH-major] Breast Neoplasms / surgery. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Positron-Emission Tomography. ROC Curve. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452249.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


64. Milot L, Guindi M, Gallinger S, Moulton CA, Brock KK, Dawson LA, Haider MA: MR imaging correlates of intratumoral tissue types within colorectal liver metastases: a high-spatial-resolution fresh ex vivo radiologic-pathologic correlation study. Radiology; 2010 Mar;254(3):747-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In seven consecutive patients undergoing hepatic resection for liver metastases (primary colorectal in six, breast mistaken for colorectal in one), the resected fresh ex vivo liver specimen was examined with T1-weighted (repetition time msec/echo time msec, 9/4.4-4.8) and T2-weighted (2500/90) MR imaging by using a voxel size of 0.47 x 0.7 x 2 mm.
  • This SI pattern is unusual for common benign liver lesions and may be helpful in the MR imaging diagnosis of colorectal liver metastases. (c) RSNA, 2010.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. In Vitro Techniques. Linear Models. Male. Middle Aged. Neoplasm Staging. Prospective Studies


65. Mendes RA, Carvalho JF, Waal Iv: An overview on the expression of cyclooxygenase-2 in tumors of the head and neck. Oral Oncol; 2009 Oct;45(10):e124-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview on the expression of cyclooxygenase-2 in tumors of the head and neck.
  • Cyclooxygenase-2 (COX-2) levels are increased in various tumors, particularly those involving the esophagus, stomach, breast, pancreas, lung, colon, skin, urinary bladder, prostate and head and neck.
  • Thus, the literature shows increasing evidence that overexpression of the COX-2 plays an important role in tumor growth and spread of tumors by interfering with different biological processes such as cell proliferation, cellular adhesion, immune surveillance, apoptosis, and angiogenesis.
  • Furthermore, the expression of COX-2 might shed some light over the physiopathology and clinical behavior of tumors of the head and neck, including benign odontogenic neoplasms of the jaws with an aggressive behavior, such as keratocystic odontogenic tumors (KCOT).
  • Ultimately, the research of molecular markers associated with the biological behavior of tumors will help to understand the underlying molecular mechanisms and to predict the clinical outcome, leading to the development of new therapeutic applications, such as molecular-targeted treatment and patient tailored therapy.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Head and Neck Neoplasms / metabolism. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19457709.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Prostaglandins; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


66. Radke I, Götte M, Kersting C, Mattsson B, Kiesel L, Wülfing P: Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer; 2006 Aug 7;95(3):347-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
  • The aim of this study was to investigate the expression of the protein tyrosine phosphatases (PTP) PRL-1, PRL-2, and PRL-3 in human breast cancer and to evaluate its clinical and prognostic significance.
  • PRL-PTP mRNA expression was examined in malignant (n = 7) and nonmalignant (n = 7) cryoconserved breast tissue samples as well as in eight breast cancer cell lines by RT-PCR.
  • Furthermore, protein expression of PRL-3 was analysed semiquantitatively by immunohistochemistry in ductal breast carcinoma in situ (n = 135) and invasive breast cancer (n = 147) by use of tissue microarray technology (TMA).
  • In 24 lymph node-positive patients we selected the corresponding lymph node metastases for analysis of PRL-3 expression, and a validation set (n = 99) of invasive breast cancer samples was examined.
  • PRL-3 mRNA expression was significantly higher in malignant compared to benign breast tissue.
  • Staining of TMAs showed PRL-3 expression in 85.9% ductal carcinoma in situ and 75.5% invasive breast carcinomas.
  • Analysis of survival parameters revealed a shorter disease-free survival (DFS) in patients with PRL-3-positive carcinomas, and in particular a significantly shorter DFS in nodal-positive patients with PRL-3 overexpressing tumours as compared to PRL-3-negative breast carcinomas (66+/-7 months (95% CI, 52-80) vs 97+/-9 months (95% CI, 79-115); P = 0.032).
  • Moreover, we found a more frequent expression of PRL-3 in lymph node metastases as compared to the primary tumours (91.7 vs 66.7%; P = 0.033).
  • Our results suggest that PRL-3 might serve as a novel prognostic factor in breast cancer, which may help to predict an adverse disease outcome.
  • [MeSH-major] Breast Neoplasms / genetics. Cell Cycle Proteins / genetics. Membrane Proteins / genetics. Neoplasm Proteins / genetics. Protein Tyrosine Phosphatases / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Female. Follow-Up Studies. Gene Expression Profiling. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / genetics. Middle Aged. Neoplasm Invasiveness. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors. Sensitivity and Specificity. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):945-51 [14737124.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Feb;49(2):91-107 [15012971.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2393-400 [15073116.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1630-7 [15117985.001]
  • [Cites] Pathobiology. 2004;71(4):176-84 [15263806.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6 [15133662.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] Mol Cell Biol. 1991 Jan;11(1):381-90 [1986233.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Feb;37(2):97-114 [11166583.001]
  • [Cites] Breast Cancer Res Treat. 2001 Apr;66(3):201-8 [11510691.001]
  • [Cites] Oncology. 2001;61 Suppl 2:67-72 [11694790.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46659-68 [12235145.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14):1255-64 [12516958.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] Dev Biol. 2003 May 1;257(1):205-19 [12710968.001]
  • [Cites] Nat Med. 2003 Jun;9(6):713-25 [12778170.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2716-22 [12782572.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jul;129(7):375-82 [12884024.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):167-80 [7831528.001]
  • [Cites] Hum Genet. 1995 Nov;96(5):532-8 [8529999.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2013-6 [8616842.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):455-8 [9291439.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7 [9514946.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7857-66 [15520192.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7318-28 [15534108.001]
  • [Cites] Int J Oncol. 2005 Apr;26(4):951-60 [15753989.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):945-51 [15326366.001]
  • [Cites] Mol Cancer Ther. 2005 Nov;4(11):1653-61 [16275986.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):219-29 [16505094.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1720-8 [15841074.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1569-83 [16148022.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6835-9 [16203771.001]
  • [Cites] Fertil Steril. 2005 Oct;84 Suppl 2:1173-9 [16210009.001]
  • (PMID = 16832410.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 3.1.3.48 / PTP4A1 protein, human; EC 3.1.3.48 / PTP4A2 protein, human; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC2360632
  •  go-up   go-down


67. Iyengar P, Ali SZ, Brogi E: Fine-needle aspiration cytology of mammary adenomyoepithelioma: a study of 12 patients. Cancer; 2006 Aug 25;108(4):250-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adenomyoepithelioma (AME) of the breast is a rare neoplasm that is characterized by a biphasic proliferation of epithelial and myoepithelial cells.
  • METHODS: The authors conducted a retrospective evaluation of cytologic findings in fine-needle aspiration biopsy (FNAB) material from 12 patients with histologically proven benign AMEs of the breast.
  • None of the patients were diagnosed originally with AME: Two tumors were classified as benign and consistent with fibroadenoma, 6 tumors were atypical, 2 tumors were suspicious for carcinoma, and 2 tumors were positive for malignant cells.
  • CONCLUSIONS: Because of the varied histology of AME, cytologic diagnosis of this neoplasm can be very challenging.
  • Conservative diagnosis and further histologic evaluation is recommended for these patients.
  • [MeSH-major] Adenoma / pathology. Biopsy, Fine-Needle. Breast Neoplasms / pathology. Myoepithelioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Trials as Topic. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16544319.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Schiffhauer LM, Boger JN, Bonfiglio TA, Zavislan JM, Zuley M, Fox CA: Confocal microscopy of unfixed breast needle core biopsies: a comparison to fixed and stained sections. BMC Cancer; 2009;9:265
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal microscopy of unfixed breast needle core biopsies: a comparison to fixed and stained sections.
  • BACKGROUND: Needle core biopsy, often in conjunction with ultrasonic or stereotactic guided techniques, is frequently used to diagnose breast carcinoma in women.
  • This paper reports the progress in developing techniques to rapidly screen needle core breast biopsy and surgical specimens at the point of care.
  • CSLM requires minimal tissue processing and has the potential to reduce the time from excision to diagnosis.
  • METHODS: Needle core breast specimens from 49 patients were imaged at the time of biopsy.
  • These lesions had been characterized under the Breast Imaging Reporting And Data System (BI-RADS) as category 3, 4 or 5.
  • Immediately following imaging, the specimens were fixed in buffered formalin and submitted for histological processing and pathological diagnosis.
  • RESULTS: The pathologic diagnoses by standard histology were 7 invasive ductal carcinomas, 2 invasive lobular carcinomas, 3 ductal carcinomas in-situ (CIS), 21 fibrocystic changes/proliferative conditions, 9 fibroadenomas, and 5 other/benign; two were excluded due to imaging difficulties.
  • Morphologic and cellular features of benign and cancerous lesions were identified in the confocal images and were comparable to standard histologic sections of the same tissue.
  • Morphologic and cellular features of benign and cancerous lesions were identified in the confocal images.
  • Additional studies are needed to 1.) establish correlation of the confocal and traditional histologic images for the various diseases of the breast; 2.) validate diagnostic use of CSLM and; 3.) further define features of borderline lesions such as well-differentiated ductal CIS vs. atypical hyperplasia.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Microscopy, Confocal / methods
  • [MeSH-minor] Biopsy. Cell Proliferation. Contrast Media / pharmacology. Female. Humans. Medical Oncology / methods. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 Oct;33(10):975-82 [12395369.001]
  • [Cites] Pancreatology. 2001;1(1):48-57 [12120268.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1137-43 [11710924.001]
  • [Cites] Surgery. 2000 Dec;128(6):1088-1100; discussion 1100-1 [11114647.001]
  • [Cites] BMC Cancer. 2008;8:21 [18215290.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051602 [16292950.001]
  • [Cites] J Invest Dermatol. 1999 Sep;113(3):293-303 [10469324.001]
  • [Cites] Clin Dermatol. 2003 Sep-Oct;21(5):359-69 [14678715.001]
  • [Cites] Dermatol Surg. 2003 Aug;29(8):839-46 [12859385.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051901 [17994884.001]
  • (PMID = 19650910.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC3087331
  •  go-up   go-down


69. Jing F, Zhang J, Tao J, Zhou Y, Jun L, Tang X, Wang Y, Hai H: Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. Onkologie; 2007 Feb;30(1-2):14-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients.
  • BACKGROUND: We investigated the hypermethylation status in serum of sporadic breast cancer patients.
  • MATERIAL AND METHODS: The hypermethylation status of BRCA1, p16 and 14-3-3sigma in cancerous tissues and the paired serum of 38 sporadic breast cancer patients was examined by methylation-specific PCR (MSP) assay.
  • Normal and benign tissue and serum control DNA were also examined to determine the specificity of hypermethylation.
  • RESULTS: Hypermethylation of 1 or more genes was found in 36/38 (95%) of sporadic breast cancers.
  • No methylated products of BRCA1, p16 and 14-3-3sigma were observed in serum DNA from healthy women and patients with benign tissue specimens.
  • A gene unmethylated in the tumor DNA was always found to be unmethylated in matched serum DNA.
  • CONCLUSIONS: Hypermethylation of BRCA1, p16 and 14-3-3sigma is present in all histologic types, stages and grades in sporadic breast cancer and can be detected in serum DNA.
  • It signifies that serum-based hypermethylation screening may enhance early detection of sporadic breast cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / genetics. Breast Neoplasms / blood. Breast Neoplasms / genetics. DNA Methylation. Genes, Tumor Suppressor
  • [MeSH-minor] 14-3-3 Proteins. Adult. Aged. Cyclin-Dependent Kinase Inhibitor p16 / blood. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Mutational Analysis / methods. Exonucleases / blood. Exonucleases / genetics. Exoribonucleases. Female. Humans. Middle Aged. Neoplasm Proteins / blood. Neoplasm Proteins / genetics. Reproducibility of Results. Sensitivity and Specificity. Ubiquitin-Protein Ligases / blood. Ubiquitin-Protein Ligases / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264521.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Neoplasm Proteins; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human; EC 6.3.2.- / BRAP protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


70. Liu HM, Wu FL, Chen X, Ye CS, Deng YJ: [Value of ultrasonographic grading with high-frequency probes in distinguishing breast tumors]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct;29(10):2115-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of ultrasonographic grading with high-frequency probes in distinguishing breast tumors].
  • OBJECTIVE: To investigate the value of ultrasonographic grading with high-frequency probes in differentiating benign and malignant breast tumors.
  • METHODS: Sixty-four women (mean age 44.5-/+13.7 years) with 79 breast tumors underwent high-frequency ultrasonography to examine the tumor number, size, aspect ratio, shape, boundaries, encapsulation, pseudopod, internal and rear echoes, calcifications, blood perfusion, abnormality lymph nodes in the axilla.
  • The tumors were graded based on these findings using a 10-point grading system.
  • RESULTS: Between the 46 women with benign tumors and 18 with malignant tumors, no significant differences were found in the mean tumor number (1.5-/+1.3 vs 1.1-/+0.3, P>0.05) or size (55.0-/+19.2 mm vs 19.8-/+8.3 mm, P>0.05), but the mean age (41.4-/+12.4 years vs 52.4-/+14.1 years) and ultrasonographic grade (2.8-/+2.2 vs 7.3-/+1.7, P<0.05) differed significantly.
  • The ultrasonographic grade of the breast tumors showed an obvious correlation to the nature of the tumors (r=0.695, P<0.001).
  • CONCLUSION: Grading of breast tumors with high-frequency ultrasonography helps evaluate the nature of the tumors, and a higher score suggests increased probability of malignancy.
  • [MeSH-major] Breast Diseases / ultrasonography. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Grading. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861280.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


71. Ravindra S, Suguna BV: Cytomorphology of tubular adenoma breast--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):267-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology of tubular adenoma breast--a case report.
  • Tubular adenoma a 'pure adenoma' is a benign neoplasm of breast presenting clinically like fibroadenoma.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Fibroadenoma / pathology. Fibrocystic Breast Disease / pathology. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933735.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 7
  •  go-up   go-down


72. Rego MF, Navarrete MA, Facina G, Falzoni R, Silva R, Baracat EC, Nazario AC: Analysis of human mammary fibroadenoma by Ki-67 index in the follicular and luteal phases of menstrual cycle. Cell Prolif; 2009 Apr;42(2):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Fibroadenoma is the most common benign mammary condition among women aged 35 or younger.
  • MATERIALS AND METHODS: Ninety eumenorrheic women were selected for tumour excision; they were assigned to either of the two groups, according to their phase of menstrual cycle.
  • RESULTS: Both groups were found to be homogeneous relative to age, menarche, body mass index, previous gestation, parity, breastfeeding, number of fibroadenomas, family history of breast cancer and tabagism.
  • Median tumour size was 2.0 cm and no relationship between proliferative activity and nodule diameter was observed.
  • The present study contributes to clarifying that fibroadenoma is a neoplasm and does not undergo any change in the proliferative activity during the menstrual cycle.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Proliferation. Fibroadenoma / pathology. Follicular Phase / metabolism. Ki-67 Antigen / metabolism. Luteal Phase / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Breast Feeding / statistics & numerical data. Female. Humans. Obesity / complications. Progesterone / blood. Tobacco Use Disorder / complications. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317807.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


73. Wishart GC, Campisi M, Boswell M, Chapman D, Shackleton V, Iddles S, Hallett A, Britton PD: The accuracy of digital infrared imaging for breast cancer detection in women undergoing breast biopsy. Eur J Surg Oncol; 2010 Jun;36(6):535-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The accuracy of digital infrared imaging for breast cancer detection in women undergoing breast biopsy.
  • BACKGROUND: Mammography has a lower sensitivity for breast cancer detection in younger women and those with dense breasts.
  • Recent improvements in digital infrared breast imaging suggest there may be a role for this technology and we have studied its performance in 100 women prior to breast needle core biopsy (CB).
  • METHODS: All patients were imaged using a digital infrared breast (DIB) scan (Sentinel BreastScan) prior to breast biopsy.
  • RESULTS: Of 106 biopsies performed in 100 women, 65 were malignant and 41 were benign.
  • CONCLUSION: DIB using NoTouch is an effective adjunctive test for breast cancer detection in women under 70 and appears to be particularly effective in women under 50 where maximal sensitivity (78%) and specificity (75%) were observed.
  • [MeSH-major] Breast Neoplasms / pathology. Thermography / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Humans. Infrared Rays. Middle Aged. Neoplasm Staging. Neural Networks (Computer). Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Rev Clin Oncol. 2010 Sep;7(9):483 [20824903.001]
  • (PMID = 20452740.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


74. Rozenchan PB, Carraro DM, Brentani H, de Carvalho Mota LD, Bastos EP, e Ferreira EN, Torres CH, Katayama ML, Roela RA, Lyra EC, Soares FA, Folgueira MA, Góes JC, Brentani MM: Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts. Int J Cancer; 2009 Dec 15;125(12):2767-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts.
  • The importance of epithelial-stroma interaction in normal breast development and tumor progression has been recognized.
  • To identify genes that were regulated by these reciprocal interactions, we cocultured a nonmalignant (MCF10A) and a breast cancer derived (MDA-MB231) basal cell lines, with fibroblasts isolated from breast benign-disease adjacent tissues (NAF) or with carcinoma-associated fibroblasts (CAF), in a transwell system.
  • Our data indicate that interactions between breast fibroblasts and basal epithelial cells resulted in alterations in the genomic profiles of both cell types which may help to clarify some aspects of this heterotypic signaling.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Epithelial Cells / metabolism. Fibroblasts / metabolism. Gene Expression Profiling. Neoplasm Proteins / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Breast / cytology. Cell Proliferation. Coculture Techniques. Female. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 UICC.
  • (PMID = 19530251.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


75. Wright TG, Singh VK, Li JJ, Foley JH, Miller F, Jia Z, Elliott BE: Increased production and secretion of HGF alpha-chain and an antagonistic HGF fragment in a human breast cancer progression model. Int J Cancer; 2009 Sep 1;125(5):1004-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased production and secretion of HGF alpha-chain and an antagonistic HGF fragment in a human breast cancer progression model.
  • Invasive human breast carcinomas frequently coexpress increased hepatocyte growth factor (HGF) and its receptor Met, suggesting that establishment of an autocrine HGF loop is important in malignant disease.
  • This study examines the expression patterns of HGF and Met activation during tumorigenesis and metastasis using a MCF10A-based model of Ha-Ras-induced human breast cancer progression.
  • Compared to the benign parent cell line, premalignant and malignant cell lines exhibit increased secretion of full length HGF alpha-chain and elevated Met tyrosine phosphorylation in complete medium.
  • Epitope mapping of the approximately 55 kDa HGF fragment supports the presence of the N-terminal domain of the HGF alpha-chain with a truncation in the C-terminal domain.
  • These results are the first demonstration of an antagonistic approximately 55 kDa HGF fragment secreted during breast carcinoma progression, which may have a negative regulatory effect on HGF signaling in premalignant breast epithelial cells.
  • [MeSH-major] Breast Neoplasms / metabolism. Hepatocyte Growth Factor / metabolism. Peptide Fragments / metabolism. Proto-Oncogene Proteins c-met / metabolism
  • [MeSH-minor] Blotting, Western. Cell Transformation, Neoplastic. Culture Media, Conditioned / pharmacology. Disease Progression. Genes, ras. Humans. Mesoderm / cytology. Mesoderm / metabolism. Neoplasm Invasiveness. Phosphorylation. Tyrosine / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC.
  • (PMID = 19415747.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Peptide Fragments; 42HK56048U / Tyrosine; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


76. Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defazio A: Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer; 2005 Dec 20;117(6):1049-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
  • Since tumor protein D52 (TPD52) has been identified as a chromosome 8q21 amplification target in breast and prostate carcinoma, we compared TPD52 expression in normal ovarian epithelium (n = 9), benign serous adenomas (n = 11), serous borderline tumors (n = 6) and invasive carcinomas of the major histologic subtypes (n = 57) using immunohistochemistry.
  • These analyses revealed that all normal ovarian epithelium samples and benign serous tumors were predominantly TPD52-negative, whereas TPD52 was overexpressed in most (44/57; 77%) ovarian carcinomas regardless of histologic subtype.
  • [MeSH-major] Gene Amplification / genetics. Gene Expression. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. CA-125 Antigen / blood. Chromosomes, Human, Pair 8. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Ovary / chemistry

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15986428.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Neoplasm Proteins; 0 / TPD52 protein, human
  •  go-up   go-down


77. Sandhya B, Babu V, Parthasarathy G, Kate V, Ananthakrishnan N, Krishnan R: Primary leiomyosarcoma of the breast: A case report and review of literature. Indian J Surg; 2010 Jul;72(Suppl 1):286-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leiomyosarcoma of the breast: A case report and review of literature.
  • Leiomyosarcomas of the breast are rare tumours.
  • We describe herein a case of primary leiomyosarcoma of the breast in a 54-year-old woman whose preoperative clinical and cytological findings indicated a benign breast tumour.
  • Histopathological examination of the mastectomy specimen suggested a diagnosis of leiomyosarcoma, which was subsequently confirmed by immunohistochemical analysis.
  • Primary leiomyosarcoma of the breast is very rare and is difficult to diagnose preoperatively as it needs immuno-histochemical staining.
  • It is necessary to excise the tumour with sufficient margins to prevent local recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1997;27(11):1082-5 [9413066.001]
  • [Cites] Pathol Oncol Res. 2001;7(2):151-3 [11458280.001]
  • [Cites] Surg Today. 2002;32(8):716-9 [12181723.001]
  • [Cites] Arch Gynecol Obstet. 2003 Feb;267(4):233-5 [12592426.001]
  • [Cites] Breast J. 2003 Nov-Dec;9(6):494-6 [14616945.001]
  • [Cites] Diagn Cytopathol. 2003 Sep;29(3):172-8 [12951688.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):783-6 [14526679.001]
  • (PMID = 23133273.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451846
  • [Keywords] NOTNLM ; Breast / Phyllodes Sandhya / Stromal tumours
  •  go-up   go-down


78. Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lokshin AE, Lo JY: Do serum biomarkers really measure breast cancer? BMC Cancer; 2009 May 28;9:164
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do serum biomarkers really measure breast cancer?
  • BACKGROUND: Because screening mammography for breast cancer is less effective for premenopausal women, we investigated the feasibility of a diagnostic blood test using serum proteins.
  • RESULTS: The classifiers were able to distinguish normal tissue from breast cancer with a classification performance of AUC = 0.82 +/- 0.04 with the proteins MIF, MMP-9, and MPO.
  • The classifiers distinguished normal tissue from benign lesions similarly at AUC = 0.80 +/- 0.05.
  • However, the serum proteins of benign and malignant lesions were indistinguishable (AUC = 0.55 +/- 0.06).
  • The classification tasks of normal vs. cancer and normal vs. benign selected the same top feature: MIF, which suggests that the biomarkers indicated inflammatory response rather than cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biomark. 2006;2(6):235-48 [17264395.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):334-41 [17301268.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2470-6 [17594124.001]
  • [Cites] Med Decis Making. 2000 Jul-Sep;20(3):323-31 [10929855.001]
  • [Cites] Med Phys. 2000 Jul;27(7):1509-22 [10947254.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1):53-67 [11254867.001]
  • [Cites] Proteomics. 2001 Oct;1(10):1205-15 [11721633.001]
  • [Cites] Science. 2002 Jun 28;296(5577):2391-4 [12089442.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1194-7 [12142372.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Expert Opin Ther Targets. 2003 Apr;7(2):153-64 [12667094.001]
  • [Cites] Proteomics. 2003 Apr;3(4):433-9 [12687611.001]
  • [Cites] J Neurochem. 2003 Jul;86(2):519-28 [12871593.001]
  • [Cites] Bioinformatics. 2003 Aug 12;19(12):1484-91 [12912828.001]
  • [Cites] Thyroid. 2003 Jun;13(6):547-51 [12930598.001]
  • [Cites] Radiology. 2003 Oct;229(1):3-8 [14519861.001]
  • [Cites] Med Phys. 2004 Jan;31(1):81-90 [14761024.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):559-63 [14726467.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1767-75 [15386335.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5B):3221-4 [15510614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Dec;73(12):4329-33 [188033.001]
  • [Cites] Radiology. 1984 Feb;150(2):335-7 [6691085.001]
  • [Cites] Radiology. 1987 Jan;162(1 Pt 1):167-70 [3024209.001]
  • [Cites] Invest Radiol. 1988 Oct;23(10):729-33 [3056868.001]
  • [Cites] Blood. 1989 May 1;73(6):1504-12 [2653458.001]
  • [Cites] Breast Cancer Res Treat. 1989 Mar;13(2):123-33 [2730960.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):193-9 [2295042.001]
  • [Cites] Endocrinol Jpn. 1989 Dec;36(6):873-9 [2483831.001]
  • [Cites] Immunol Today. 1993 Oct;14(10):506-12 [7506035.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Mar;80(3):922-6 [7883851.001]
  • [Cites] J Clin Invest. 1995 Mar;95(3):1370-6 [7883984.001]
  • [Cites] J Exp Med. 1996 Jan 1;183(1):147-57 [8551218.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):340-1 [8909643.001]
  • [Cites] FASEB J. 1996 Dec;10(14):1607-13 [9002552.001]
  • [Cites] Clin Biochem. 1997 Feb;30(1):53-6 [9056110.001]
  • [Cites] Infect Immun. 1997 Nov;65(11):4734-7 [9353058.001]
  • [Cites] Cell. 1998 May 1;93(3):411-22 [9590175.001]
  • [Cites] Biochimie. 1998 Aug-Sep;80(8-9):673-87 [9865490.001]
  • [Cites] J Urol. 1999 Aug;162(2):293-306 [10411025.001]
  • [Cites] Science. 1999 Jul 30;285(5428):727-9 [10426993.001]
  • [Cites] Oncology. 2004;67(5-6):359-67 [15713991.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):529-34 [15863156.001]
  • [Cites] J Thromb Haemost. 2008 Sep;6(9):1586-94 [18541003.001]
  • [Cites] Cancer Control. 2007 Oct;14(4):360-8 [17914336.001]
  • [Cites] Pathol Oncol Res. 2007;13(4):360-4 [18158573.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1508-17 [18257519.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1419-26 [18303830.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1395-402 [18303834.001]
  • [Cites] Cancer Biomark. 2008;4(2):73-81 [18503158.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] J Proteome Res. 2009 Jan;8(1):362-73 [19053527.001]
  • [Cites] Cancer Treat Rev. 2000 Apr;26(2):91-102 [10772967.001]
  • [Cites] Bioinformatics. 2005 May 15;21(10):2394-402 [15713736.001]
  • [Cites] Intern Med J. 2005 Jul;35(7):419-26 [15958113.001]
  • [Cites] Tumour Biol. 2005 Nov-Dec;26(6):281-93 [16254457.001]
  • [Cites] Clin Chem. 2006 Mar;52(3):345-51 [16410341.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(1):83-90 [16322896.001]
  • [Cites] Hell J Nucl Med. 2006 Jan-Apr;9(1):60-4 [16617400.001]
  • [Cites] BMC Bioinformatics. 2006;7:197 [16606446.001]
  • [Cites] IEEE Trans Med Imaging. 2006 May;25(5):571-81 [16689261.001]
  • [Cites] Br J Haematol. 2006 Jun;133(6):692-4 [16704450.001]
  • [Cites] Brain. 2006 Nov;129(Pt 11):3042-50 [17071923.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19472-7 [17159154.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Proteomics. 2007 Jan;7(2):299-312 [17205601.001]
  • (PMID = 19476629.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 84955; United States / NCI NIH HHS / CA / R01 CA-112437-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2696469
  •  go-up   go-down


79. Huang YD, Zhang S: [Focal adhesion kinase expression and angiogenesis in breast carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep;27(9):1370-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Focal adhesion kinase expression and angiogenesis in breast carcinoma].
  • OBJECTIVE: To investigate the expression of focal adhesion kinase (FAK) in breast carcinoma tissues and its association with microvessel density (MVD), and explore the relationship between FAK-mediated cell signaling and angiogenesis in breast carcinoma.
  • METHODS: FAK and CD34 expressions were examined by immunohistochemistry with SP method in 88 breast carcinoma tissues and 30 tissues of benign breast disease.
  • The correlations of FAK protein expression with MVD marked with CD34 and clinicopathological parameters were analyzed in breast carcinoma.
  • RESULTS: In the 88 breast carcinomas, the positivity rate of FAK was 68.2% (60/88) with MVD of (34.52-/+13.11) /HPE, showing significant differences from those of the benign disease group (P<0.01).
  • FAK expression and MVD in breast carcinoma tissues were positively related to tumor size, axillary lymph node metastasis and clinical stage (P<0.05), but not to the patients' age or histopathological grade of the tumors (P>0.05).
  • In breast carcinoma, the expression of FAK was positively related to MVD (P<0.01).
  • CONCLUSIONS: FAK protein expression and MVD are closely correlated with the invasion and metastasis of breast carcinoma.
  • FAK expression can promote angiogenesis of breast carcinoma.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / physiopathology. Focal Adhesion Protein-Tyrosine Kinases / metabolism. Gene Expression Regulation, Neoplastic. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884781.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases
  •  go-up   go-down


80. Ben Hassouna J, Damak T, Gamoudi A, Chargui R, Khomsi F, Mahjoub S, Slimene M, Ben Dhiab T, Hechiche M, Boussen H, Rahal K: Phyllodes tumors of the breast: a case series of 106 patients. Am J Surg; 2006 Aug;192(2):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumors of the breast: a case series of 106 patients.
  • BACKGROUND: Phyllodes tumors (PTs) of the breast are rare, and their prognosis and treatment are still subject of discussion.
  • According to criteria of Azzopardi and Salvadori, tumors were classified into 3 groups: benign (62 cases, 58.4%), borderline (16 cases, 15%), and malignant (28 cases, 26.4%).
  • Eighty-two patients (77.4%) were treated conservatively (62 benign, 11 borderline, and 9 malignant) and 24 (22.6%) by radical surgery (5 borderline and 19 malignant).
  • For malignant PTs treated by enucleation or local excision with or without reexcision of the tumor bed, the 5-year overall and disease-free survivals were 28.5% and 15.6% versus 72.7% and 73.6% when the surgery was radical (mastectomy with or without axillary dissection) (P = .12 and P = .0022).
  • The rate of recurrence was 12.2% (13) after a mean follow-up of 39 months (5 benign, 2 borderline, and 5 malignant).
  • In univariate analysis, age and recurrences are not of prognostic value for survival, whereas tumor size, histotype, necrosis, cytonuclear atypia, tumor margins, and number of mitosis were significant prognostic factors for survival.
  • CONCLUSION: According to our results, we recommend for malignant PT a simple mastectomy, whereas for borderline and benign PT, treatment is based rather on wide excision passing in healthy tissue.
  • [MeSH-major] Breast Neoplasms / diagnosis. Mastectomy / methods. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Disease-Free Survival. Female. Follow-Up Studies. Humans. Mammography. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860620.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Hirshoren N, Weinberger JM, Neuman T, Ilan O, Ben-Yaakov A: Recurrent vascular leiomyoma of the larynx: clinical and histopathologic characteristics and treatment. Ear Nose Throat J; 2010 Aug;89(8):382-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laryngeal vascular leiomyomas are uncommon benign tumors that seldom recur following complete excision.
  • The choice of excision procedure-via direct laryngoscopy or an open approach-is dictated by tumor size, the expected amount of blood loss, and any comorbidities the patient may have.
  • We report an unusual case of a recurrent laryngeal vascular leiomyoma in a 64-year-old woman who also had a concurrent parathyroid adenoma and a history of breast carcinoma.
  • [MeSH-major] Angiomyoma / surgery. Laryngeal Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adenoma / surgery. Female. Humans. Laryngoscopy. Larynx / pathology. Laser Therapy. Magnetic Resonance Imaging. Medical Records. Middle Aged. Neoplasms, Multiple Primary / surgery. Parathyroid Neoplasms / surgery. Reoperation. Respiration Disorders / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20737377.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Fiorucci F, Conti V, Lucantoni G, Patrizi A, Fiorucci C, Giannunzio G, Di Michele L: Sarcoidosis of the breast: a rare case report and a review. Eur Rev Med Pharmacol Sci; 2006 Mar-Apr;10(2):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoidosis of the breast: a rare case report and a review.
  • Sarcoidosis is an idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis.
  • Breast involvement is extremely rare, but, when present, it could be confused with a benign or, more important, a malignant neoplasm.
  • We have reported a case of sarcoidosis of the breast in a 51 years old woman with systemic manifestations of sarcoidosis (arthralgias and uveitis) associated with a breast mass and with a clinical history of fibrocystic mastopathy.
  • A chest X-ray and a Computed Tomography (CT), with raised serum levels of Angiotensin Converting Enzyme (ACE), were compatible with a diagnosis of sarcoidosis.
  • The mammography and ultrasonogram showed a solitary little nodular lesion localized in the breast.
  • A breast cancer in a patient with sarcoidosis?
  • To answer this question, the patient performed breast surgery under general anaesthesia and bioptic microscopic examination showed a typical sarcoid granuloma.
  • [MeSH-major] Breast Diseases / diagnosis. Sarcoidosis / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged. Tomography, X-Ray Computed. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16705947.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 6
  •  go-up   go-down


83. Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, Palmerini E, Briccoli A, Pignotti E, Balladelli A, Picci P: Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol; 2006 Dec;28(12):774-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
  • Twenty-six patients (2.15%) developed a second malignant neoplasm at a median of 7.6 years (1 to 25 y) after primary osteosarcoma treatment.
  • Second neoplasms were leukemia (10), breast (7), lung (2), kidney (2), central nervous system cancer (2), soft tissue (1), parotid (1), and colon (1).
  • The rate of second neoplasms was significantly higher in female patients, and the latent period shorter in hematologic tumors compared with solid tumors.
  • The rate of second malignancies observed in the osteosarcoma group was significantly higher than that observed in the control group of 1160 patients with benign tumors treated in the same period at our Institute (2.2% vs. 0.8%, P<0.009).
  • Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented.
  • [MeSH-major] Neoplasms, Second Primary / epidemiology. Osteosarcoma
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Incidence. Infant. Male. Neoplasms / drug therapy. Neoplasms / epidemiology. Retrospective Studies. Risk Factors. Sex Factors. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164644.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Maxwell AJ: Ultrasound-guided vacuum-assisted excision of breast papillomas: review of 6-years experience. Clin Radiol; 2009 Aug;64(8):801-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound-guided vacuum-assisted excision of breast papillomas: review of 6-years experience.
  • AIM: To review the outcome of vacuum-assisted removal of breast papillomas performed in the Bolton Breast Unit.
  • MATERIALS AND METHODS: Twenty-six benign breast papillomas were excised using an ultrasound-guided, vacuum-assisted technique under local anaesthetic over a 6-year period.
  • Subsequent breast imaging (mostly routine screening mammography) was reviewed and evidence of recurrence recorded.
  • All three recurrent lesions were surgically excised and confirmed to be benign papillomas.
  • [MeSH-major] Breast Neoplasms / surgery. Papilloma, Intraductal / surgery. Ultrasonography, Interventional
  • [MeSH-minor] Aged. Biopsy / methods. Breast / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / surgery. Neoplasm Recurrence, Local / ultrasonography. Treatment Outcome. Ultrasonography, Mammary. Vacuum

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19589419.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Tozaki M, Yamashiro N, Suzuki T, Kawano N, Ozaki S, Sakamoto N, Abe S, Ogawa T, Katayama N, Tsunoda Y, Fukuma E: MR-guided vacuum-assisted breast biopsy: is it an essential technique? Breast Cancer; 2009;16(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR-guided vacuum-assisted breast biopsy: is it an essential technique?
  • Histopathological findings were invasive ductal carcinoma in one (3%); ductal carcinoma in situ (DCIS) in seven (23%); and benign in 22 (73%).
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Biopsy, Needle / instrumentation. Biopsy, Needle / methods. Female. Humans. Mammography / instrumentation. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807122.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


86. Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ: Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med; 2006 Oct;130(10):1516-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
  • CONTEXT: Phyllodes tumors (PTs) of the breast are biphasic neoplasms composed of epithelium and a spindle-cell stroma.
  • Currently, PTs are classified as benign, borderline, or malignant based on histopathologic features.
  • DESIGN: Sixteen benign, 8 borderline, and 6 malignant PTs with follow-up were examined for reactivity across a panel of immunohistochemical stains, including c-Kit, endothelin 1, p16, p21, p53, and Ki-67.
  • Tumor variables were compared among tumor subgroups and between tumors that did and did not recur.
  • RESULTS: Of the 30 PTs, 4 recurred (1 benign, 2 borderline, 1 malignant).
  • One patient with a malignant tumor died of metastatic disease 34 months after initial diagnosis.
  • The overall positive rate of c-Kit immunoreactivity was 13% in benign, 63% in borderline, and 67% in malignant PTs.
  • Endothelin 1 epithelial cytoplasmic staining was seen in 100% of benign, 50% of borderline, and 17% of malignant PTs.
  • Additionally, p16, p21, p53, and Ki-67 were differentially expressed among benign, borderline, and malignant tumors.
  • CONCLUSIONS: Stromal c-Kit positivity and epithelial endothelin 1 negativity are more often associated with malignant PTs; however, only positive margin status is significantly associated with tumor behavior.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Phyllodes Tumor / metabolism. Phyllodes Tumor / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Disease Progression. Endothelin-1 / metabolism. Epithelium / metabolism. Female. Humans. Immunohistochemistry / methods. Ki-67 Antigen / metabolism. Mastectomy. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Proto-Oncogene Proteins c-kit / metabolism. Staining and Labeling. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090194.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Endothelin-1; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


87. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to evaluate the expression of topoIIalpha in various types of salivary gland tumors and its biological significance.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Salivary Gland Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


88. Pierce A, Saldova R, Abd Hamid UM, Abrahams JL, McDermott EW, Evoy D, Duffy MJ, Rudd PM: Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients. Glycobiology; 2010 Oct;20(10):1283-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients.
  • One of the most urgent requirements in breast cancer is the development of a blood-based test for early detection and prognosis.
  • Previously published results found a significant difference between specific glycan levels in patients with advanced breast cancer and healthy controls.
  • Agalactosyl biantennary glycans (FA2) and glycans containing the sialyl Lewis x epitope (A3F1G1 and A2F1G1) were measured using high throughput normal-phase high-performance liquid chromatography in combination with exoglycosidase digestions in sera from 52 patients with early breast cancer (21 with lymph node-negative and 20 with lymph node-positive disease) and 134 women with benign breast disease.
  • Lymph node status is the single most important determinant of survival in early stage breast cancer.
  • As high levels of these glycans were associated with nodal metastases, their measurement may provide a new non-invasive approach to determining prognosis in women with newly diagnosed breast cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / blood. Breast Neoplasms / blood. Carcinoma, Ductal, Breast / blood. Carcinoma, Lobular / blood. Lymph Nodes / metabolism. Polysaccharides / blood
  • [MeSH-minor] Antigens, CD15 / blood. Axilla. Chromatography, High Pressure Liquid. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20581008.001).
  • [ISSN] 1460-2423
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Polysaccharides; 0 / sialyl Lewis X antigen
  •  go-up   go-down


89. Navas Cañete A, Olcoz Monreal FJ, García Laborda E, Pérez Aznar JM: [Pseudoangiomatous stromal hyperplasia: magnetic resonance findings in two cases]. Radiologia; 2007 Jul-Aug;49(4):275-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hiperplasia pseudoangiomatosa estromal: hallazgos en resonancia magnética de dos casos.
  • Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast tumor of uncertain etiology, although marked hormonal influence clearly plays a role in this disease.
  • The differential diagnosis is important because this is an uncommon lesion that can simulate malignant lesions both at clinical and radiological examination, and even the histological results can be confusing.
  • [MeSH-major] Breast / pathology. Breast Diseases / diagnosis. Magnetic Resonance Imaging


90. Dillon MF, Quinn CM, McDermott EW, O'Doherty A, O'Higgins N, Hill AD: Needle core biopsy in the diagnosis of phyllodes neoplasm. Surgery; 2006 Nov;140(5):779-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle core biopsy in the diagnosis of phyllodes neoplasm.
  • BACKGROUND: Accurate identification of phyllodes neoplasms without surgical intervention is difficult, reducing the ability to manage "benign" lumps non-operatively and impacting on the open benign biopsy rate.
  • Needle core biopsy is considered to be a highly accurate technique in the diagnosis of breast carcinoma.
  • Its accuracy in the diagnosis of phyllodes neoplasm has not been established.
  • RESULTS: Twenty-three patients had phyllodes neoplasm on excisional biopsy with prior core biopsy findings as follows: phyllodes neoplasm (n=2), "equivocal" for phyllodes neoplasm (n=12), fibroadenoma (n=3), benign (n=6).
  • The false negative rate for phyllodes neoplasm was therefore 39% (n=9/23).
  • Of the total biopsy series, 35 patients had a core biopsy suggesting the possibility of phyllodes neoplasm.
  • Of these, 32% (n=11) were found to be phyllodes neoplasm on excision, 3% (n=1) phyllodes neoplasm with breast carcinoma, 6% (n=2) breast carcinoma, and 3% (n=1) sarcoma.
  • When a preference for phyllodes neoplasm (n=4) was stated on the equivocal core biopsies, excision correlated with the stated preference; this correlation also occurred in 90% (n=9/10) of core biopsies where fibroadenoma was favored.
  • CONCLUSIONS: Needle core biopsy rarely produces a definite preoperative diagnosis of phyllodes neoplasm.
  • A diagnosis of fibroadenoma or equivocal phyllodes neoplasm on core biopsy should not prevent excision if clinical suspicion remains.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Diagnostic Errors. Phyllodes Tumor / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084721.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Kisselbach C, Ristic AD, Pankuweit S, Karatolius K, Maisch B: [Women and pericardial neoplastic manifestations of the heart and pericardium]. Herz; 2005 Aug;30(5):409-15; quiz 429-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the proportions, most women believe that heart disease is a man's disease and that they will die of breast cancer.
  • Data on epidemiology and incidence are rare: there is only an estimated incidence of cardiac neoplasm at necropsy ranging from 0,001% to 0,3%.
  • The majority of the primary tumors are benign.
  • The most common tumor entity is benign cardiac myxoma.
  • Malignant heart tumors are less common.
  • Metastatic tumors of the heart are 100 times more common than the primary ones.
  • They originate mainly from melanomas, leukemias, lymphomas, and cancer, especially of the lung or breast.
  • Indeed in women breast cancer is the most common metastatic tumor associated with pericardial effusion.
  • However, more of the malignant tumors may be curable if exactly diagnosed at an earlier stage.
  • METHODS: A retrospective study was conducted of all patients with cardiac and pericardial neoplasm exactly diagnosed by endomyocardial or epicardial biopsy and pericardiocentesis, using hospital medical records and a biopsy and pericardiocentesis registry from 2000-2005 with 297 patients.
  • RESULTS: In 76 cases (25.6%) a neoplasm was the reason for a pericardial effusion.
  • 36 women suffered from the breast carcinoma (47%) and 40 males lung cancer (42%) as the firstly metastatic tumor.
  • CONCLUSION: Females are more often affected by primary cardiac tumors than males with an excellent outcome.
  • By contrast, the preventive checkup and aftercare will gain more prognostic importance, especially in case of breast cancer, to earlier recognize a secondary cardiac neoplasm by biopsy and pericardiocentesis with intrapericardial treatment of neoplastic pericarditis.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / secondary. Heart Neoplasms / epidemiology. Heart Neoplasms / secondary. Lung Neoplasms / epidemiology. Lung Neoplasms / secondary. Registries. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132244.001).
  • [ISSN] 0340-9937
  • [Journal-full-title] Herz
  • [ISO-abbreviation] Herz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


92. Rudland PS, Platt-Higgins AM, Davies LM, de Silva Rudland S, Wilson JB, Aladwani A, Winstanley JH, Barraclough DL, Barraclough R, West CR, Jones NJ: Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer. Am J Pathol; 2010 Jun;176(6):2935-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer.
  • This study examines the subcellular location and relationship with prognostic factors and patient survival of FANCD2 in breast cancer.
  • Antibodies to FANCD2 were used to immunocytochemically stain 16 benign and 20 malignant breast specimens as well as 314 primary breast carcinomas to assess its association with subcellular compartment and prognostic factors using Fisher's Exact test or with patient survival over 20 years using Wilcoxon-Gehan statistics.
  • Immunoreactive FANCD2 was found in the nucleus and cytoplasm of all 16 benign tissues, but nuclear staining was lost from a significant 19/20 malignant carcinomas (P < 0.0001).
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Fanconi Anemia Complementation Group D2 Protein / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cells, Cultured. Female. Humans. Middle Aged. Neoplasm Metastasis. Prognosis. Survival Rate


93. Zhao TT, Li JG, Li YM: [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes]. Zhonghua Zhong Liu Za Zhi; 2007 Mar;29(3):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes].
  • OBJECTIVE: To evaluate the performance of 18F-FDG PET/CT in the detection of primary breast cancer, and the staging of regional lymph nodes.
  • METHODS: Twenty four females with highly suspected breast cancer, underwent PET/CT imaging of the breast preoperatively.
  • Three nuclear medicine physicians analyzed the image and made the diagnosis.
  • 32 breast lesions were evaluated by histology, revealing 25 breast carcinomas and 7 benign pathological changes.
  • 23 patients had histological diagnosis of the breast tumor and regional lymph nodes.
  • RESULTS: 20 of 25 breast carcinomas were successfully diagnosed by FDG-PET/CT.
  • No Tis breast carcinoma was detected.
  • 75.0% of T1 breast carcinomas were detected, and with 85.7% of stage T2, 100.0% of T3.
  • As to a suspicious distant metastasis, PET/CT convinced the diagnosis.
  • CONCLUSION: As a noninvasive technique, FDG PET/CT appears to be a useful method in staging patient with breast cancer, especially in cases in which the lesion is hard to predict by routine examination.
  • In the detection of breast lesions, PET/CT doesn't seem to have a high sensitivity, especially in early stage breast cancers.
  • The high cost and the space resolution limit its use as a routine diagnostic method of breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Lymph Nodes / pathology. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649638.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


94. Seely JM, Nguyen ET, Jaffey J: Breast MRI in the evaluation of locally recurrent or new breast cancer in the postoperative patient: correlation of morphology and enhancement features with the BI-RADS category. Acta Radiol; 2007 Oct;48(8):838-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast MRI in the evaluation of locally recurrent or new breast cancer in the postoperative patient: correlation of morphology and enhancement features with the BI-RADS category.
  • BACKGROUND: While breast magnetic resonance imaging (MRI) is a highly sensitive test for detecting breast carcinoma, its specificity is lower, and several methods have been described on how to optimize specificity.
  • PURPOSE: To compare the specificity and sensitivity of the BI-RADS category with the Fischer score in breast MRI for diagnosing cancer in women previously treated for breast cancer.
  • MATERIAL AND METHODS: Women referred for evaluation of possible local recurrence or new breast cancer underwent breast MRI examination.
  • Pathologic diagnosis was obtained in all patients with enhancing lesions who had ultrasound or mammographic correlation.
  • In those without correlate, 6-, 12-, and 24-month follow-up breast MRIs were obtained.
  • RESULTS: 34 benign and 32 malignant lesions were identified in 26 of 30 patients.
  • CONCLUSION: BI-RADS category in breast MRI had the highest combination of specificity and sensitivity, and the highest interobserver correlation.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / anatomy & histology. Female. Humans. Middle Aged. Observer Variation. Postoperative Period. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851971.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Chowdary MV, Kalyan Kumar K, Mathew S, Rao L, Krishna CM, Kurien J: Biochemical correlation of Raman spectra of normal, benign and malignant breast tissues: a spectral deconvolution study. Biopolymers; 2009 Jul;91(7):539-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical correlation of Raman spectra of normal, benign and malignant breast tissues: a spectral deconvolution study.
  • The aim of this study was to understand and correlate spectral features and biochemical changes in normal, fibroadenoma and infiltrating ductal carcinoma of breast tissues using Raman spectra that were part of the spectroscopic models developed and evaluated by us earlier.
  • This study has revealed that fat (1301 and 1440 cm(-1)), collagen (1246, 1271, and 1671 cm(-1)) and DNA (1340 and 1480 cm(-1)) bands have strong presence in normal, benign and malignant breast tissues, respectively.
  • Thus the finding of this study further demonstrates the efficacy Raman spectroscopic approaches in diagnostic applications as well as in understanding molecular phenomenon in breast cancers.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Spectrum Analysis, Raman
  • [MeSH-minor] Collagen / chemistry. DNA, Neoplasm / chemistry. Female. Humans. Lipids / chemistry. Neoplasm Proteins / chemistry. Vibration

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley Periodicals, Inc.
  • (PMID = 19226625.001).
  • [ISSN] 0006-3525
  • [Journal-full-title] Biopolymers
  • [ISO-abbreviation] Biopolymers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Lipids; 0 / Neoplasm Proteins; 9007-34-5 / Collagen
  •  go-up   go-down


96. Braendle W, Kuhl H, Mueck A, Birkhäuser M, Thaler C, Kiesel L, Neulen J: [Does hormonal contraception increase the risk for tumors?]. Ther Umsch; 2009 Feb;66(2):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Does hormonal contraception increase the risk for tumors?].
  • A non-contraceptive benefit of oral hormonal contraceptives (OC) is a diminished risk for certain benign as well as malignant tumours, such as benign breast tumours, uterine fibroids and ovarian cysts.
  • Modern data do not suggest an increased risk for breast carcinoma in OC users.
  • [MeSH-major] Contraceptives, Oral, Hormonal / adverse effects. Neoplasms / chemically induced
  • [MeSH-minor] Adult. Age Factors. Case-Control Studies. Female. Genital Neoplasms, Female / chemically induced. Genital Neoplasms, Female / genetics. Humans. Long-Term Care. Middle Aged. Risk Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180433.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Hormonal
  • [Number-of-references] 47
  •  go-up   go-down


97. Elmore L, Margenthaler JA: Breast MRI surveillance in women with prior curative-intent therapy for breast cancer. J Surg Res; 2010 Sep;163(1):58-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast MRI surveillance in women with prior curative-intent therapy for breast cancer.
  • BACKGROUND: We sought to determine factors that predict the use of breast magnetic resonance imaging (MRI) surveillance in women previously treated for breast cancer and the incidence of in-breast recurrences and/or new cancers identified by MRI.
  • METHODS: We reviewed 141 patients who were treated between 2005 and 2008 who also underwent surveillance breast MRI following their treatment.
  • Patient, tumor, treatment characteristics, and MRI findings were collected.
  • Gail scores were calculated based on the patient's personal and family history prior to the breast cancer diagnosis.
  • One hundred forty-one women underwent 202 surveillance breast MRIs during the study period.
  • Two of the six were invasive breast cancers, while four were benign.
  • Patient age, Gail score, tumor stage, grade, histology, receptor status, and surgical treatment were not predictive of MRI surveillance use.
  • CONCLUSION: Prospective studies are needed to determine which patients may potentially benefit from breast MRI surveillance following curative-intent treatment.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Lobular / diagnosis. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20605594.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Varazashvili Varazi LM, Osmanova VR, Barkadze KI: [Study of serum levels of magnesium in the patients with malignant tumors]. Georgian Med News; 2006 Jul;(136):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of serum levels of magnesium in the patients with malignant tumors].
  • The main goal of the study was the evaluation of serum levels of magnesium in the practically healthy persons (control group), the patients with different malignant tumors (abdominal, pulmonary, uterus, breast, esophagus, rectum), as well as benign tumors of the breast/the uterus and the inflammatory pulmonary diseases.
  • It has been found that, in comparison with norm (23.9 mkg/ml), there is statistically significant increase in serum mean levels of Mg in the patients with malignant tumors of almost all sites investigated.
  • Abdominal/breast and lung malignant tumors are exclusive from this point of view: we have found that Mg content is near the normal mean levels in the former cases (24.7 mkg/ml and 25.3 mkg/ml, respectively) and below the average normal value in lung malignant tumors (20.5 mkg/ml).
  • It has been ascertained that there is no significant difference between the serum average levels of Mg in the control group and in the patients with pulmonary inflammatory diseases, as well as between the Mg-content in practically health persons and in those with breast benign tumors.
  • Thus, assessment of serum Mg levels seems to be useful in differential diagnosis in oncopulmonary and oncomammology clinics.
  • [MeSH-major] Biomarkers, Tumor / blood. Magnesium / blood. Neoplasms / blood
  • [MeSH-minor] Diagnosis, Differential. Humans. Prognosis

  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16905841.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; I38ZP9992A / Magnesium
  • [Number-of-references] 14
  •  go-up   go-down


99. Cho H, Kim JH: Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J Histochem Cytochem; 2009 May;57(5):513-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer.
  • To evaluate the potential of LCN2 as a biomarker, we measured serum LCN2 levels in 54 ovarian cancers, 15 borderline and 53 benign ovarian tumors, and 90 healthy controls.
  • LCN2 immunoreactivity was significantly associated with tumor differentiation (p=0.009), as well-differentiated tumors showed the highest LCN2 expression.
  • Serum LCN2 level in ovarian cancer was significantly higher than in the other study groups (p<0.001), and in accordance with IHC results, it also correlated with tumor differentiation, with well-differentiated tumors having the highest value.
  • In conclusion, LCN2 expressions are upregulated and related to tumor differentiation in ovarian cancers and should be included in future research assessing potential biomarkers for ovarian cancer.
  • [MeSH-major] Acute-Phase Proteins / biosynthesis. Biomarkers, Tumor / biosynthesis. Lipocalins / biosynthesis. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins / biosynthesis
  • [MeSH-minor] Adult. Cell Line, Tumor. Female. Fluorescent Dyes. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local. Polymerase Chain Reaction. Prognosis. Proportional Hazards Models. ROC Curve. Reference Values. Serum. Survival Analysis